<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>FDA Archives - 3DHeals</title>
	<atom:link href="https://3dheals.com/tag/fda/feed/" rel="self" type="application/rss+xml" />
	<link>https://3dheals.com/tag/fda/</link>
	<description>Discover 3D Bioprinting and Healthcare Innovations</description>
	<lastBuildDate>Fri, 22 Apr 2022 06:37:09 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://3dheals.com/wp-content/uploads/2020/09/cropped-3D-final-icon-1-1-32x32.jpg</url>
	<title>FDA Archives - 3DHeals</title>
	<link>https://3dheals.com/tag/fda/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Interview: Dr. Benjamin Holmes, CEO Nanochon</title>
		<link>https://3dheals.com/interview-benjamin-holmes-washington-dc/</link>
					<comments>https://3dheals.com/interview-benjamin-holmes-washington-dc/#respond</comments>
		
		<dc:creator><![CDATA[Jenny Chen, M.D.]]></dc:creator>
		<pubDate>Fri, 22 Oct 2021 02:41:00 +0000</pubDate>
				<category><![CDATA[Blog]]></category>
		<category><![CDATA[Influencer Interviews]]></category>
		<category><![CDATA[3D-printing]]></category>
		<category><![CDATA[additive manufacture]]></category>
		<category><![CDATA[Biomechanical Testing Facility]]></category>
		<category><![CDATA[bioprinting]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[NSF]]></category>
		<category><![CDATA[synthetic biology]]></category>
		<category><![CDATA[Technology]]></category>
		<guid isPermaLink="false">https://3dheals.com/?p=9228</guid>

					<description><![CDATA[<p><a href="https://3dheals.com">3DHeals - Discover 3D Bioprinting and Healthcare Innovations</a></p>
<p>"I think building pipelines for 3D printed technology to get from the lab to the clinic is a must. I would love to see 3D HEALS become the premier networking event for doctors, researchers, investors and strategic partners in the 3D printing space."</p>
<p>Dr. Ben Holmes is an entrepreneur, medtech executive, inventor, and scientist. He is the CEO and co-founder of Nanochon, which is commercializing a 3D printed cartilage implant for regenerating lost or damaged cartilage in joints. His academic background is in 3D printing and biomaterials for tissue engineering and regeneration. Ben is also a 3DHEALS community manager in the Washington, D.C. area. Ben will be speaking on the upcoming NAMIC/3DHEALS Startup Showcase. </p>
<p>The post <a href="https://3dheals.com/interview-benjamin-holmes-washington-dc/">Interview: Dr. Benjamin Holmes, CEO Nanochon</a> appeared first on <a href="https://3dheals.com">3DHeals</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><a href="https://3dheals.com">3DHeals - Discover 3D Bioprinting and Healthcare Innovations</a></p>

<p class="wp-block-paragraph" id="h-dr-ben-holmes-is-an-entrepreneur-medtech-executive-inventor-and-scientist-he-is-the-founder-of-nanochon-which-is-commercializing-a-3d-printed-implant-for-regenerating-lost-or-damaged-cartilage-in-joints-his-academic-background-is-in-3d-printing-and-biomaterials-for-tissue-engineering-and-regeneration"><a href="https://www.linkedin.com/in/bbhceo/" target="_blank" rel="noreferrer noopener">Dr. Ben Holmes</a> is an entrepreneur, medtech executive, inventor, and scientist. He is the CEO and co-founder of Nanochon, which is commercializing a 3D printed cartilage implant for regenerating lost or damaged cartilage in joints. His academic background is in 3D printing and biomaterials for tissue engineering and regeneration. Ben is also a 3DHEALS community manager in the Washington, D.C. area. <a href="https://3dheals.com/3dheals-startup-showcase-singapore" target="_blank" rel="noreferrer noopener">Ben will be speaking on the upcoming NAMIC/3DHEALS Startup Showcase.</a> </p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph" id="h-dr-ben-holmes-is-an-entrepreneur-medtech-executive-inventor-and-scientist-he-is-the-founder-of-nanochon-which-is-commercializing-a-3d-printed-implant-for-regenerating-lost-or-damaged-cartilage-in-joints-his-academic-background-is-in-3d-printing-and-biomaterials-for-tissue-engineering-and-regeneration"><strong>3DHEALS has recently invested in Nanochon. </strong></p>



<p class="wp-block-paragraph"></p>



<blockquote class="instagram-media" data-instgrm-captioned="" data-instgrm-permalink="https://www.instagram.com/p/CVYPb1msbRv/?utm_source=ig_embed&amp;utm_campaign=loading" data-instgrm-version="14" style=" background:#FFF; border:0; border-radius:3px; box-shadow:0 0 1px 0 rgba(0,0,0,0.5),0 1px 10px 0 rgba(0,0,0,0.15); margin: 1px; max-width:540px; min-width:326px; padding:0; width:99.375%; width:-webkit-calc(100% - 2px); width:calc(100% - 2px);"><div style="padding:16px;"> <a href="https://www.instagram.com/p/CVYPb1msbRv/?utm_source=ig_embed&amp;utm_campaign=loading" style=" background:#FFFFFF; line-height:0; padding:0 0; text-align:center; text-decoration:none; width:100%;" target="_blank" rel="noopener"> <div style=" display: flex; flex-direction: row; align-items: center;"> <div style="background-color: #F4F4F4; border-radius: 50%; flex-grow: 0; height: 40px; margin-right: 14px; width: 40px;"></div> <div style="display: flex; flex-direction: column; flex-grow: 1; justify-content: center;"> <div style=" background-color: #F4F4F4; border-radius: 4px; flex-grow: 0; height: 14px; margin-bottom: 6px; width: 100px;"></div> <div style=" background-color: #F4F4F4; border-radius: 4px; flex-grow: 0; height: 14px; width: 60px;"></div></div></div><div style="padding: 19% 0;"></div> <div style="display:block; height:50px; margin:0 auto 12px; width:50px;"><svg width="50px" height="50px" viewBox="0 0 60 60" version="1.1" xmlns="https://www.w3.org/2000/svg" xmlns:xlink="https://www.w3.org/1999/xlink"><g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd"><g transform="translate(-511.000000, -20.000000)" fill="#000000"><g><path d="M556.869,30.41 C554.814,30.41 553.148,32.076 553.148,34.131 C553.148,36.186 554.814,37.852 556.869,37.852 C558.924,37.852 560.59,36.186 560.59,34.131 C560.59,32.076 558.924,30.41 556.869,30.41 M541,60.657 C535.114,60.657 530.342,55.887 530.342,50 C530.342,44.114 535.114,39.342 541,39.342 C546.887,39.342 551.658,44.114 551.658,50 C551.658,55.887 546.887,60.657 541,60.657 M541,33.886 C532.1,33.886 524.886,41.1 524.886,50 C524.886,58.899 532.1,66.113 541,66.113 C549.9,66.113 557.115,58.899 557.115,50 C557.115,41.1 549.9,33.886 541,33.886 M565.378,62.101 C565.244,65.022 564.756,66.606 564.346,67.663 C563.803,69.06 563.154,70.057 562.106,71.106 C561.058,72.155 560.06,72.803 558.662,73.347 C557.607,73.757 556.021,74.244 553.102,74.378 C549.944,74.521 548.997,74.552 541,74.552 C533.003,74.552 532.056,74.521 528.898,74.378 C525.979,74.244 524.393,73.757 523.338,73.347 C521.94,72.803 520.942,72.155 519.894,71.106 C518.846,70.057 518.197,69.06 517.654,67.663 C517.244,66.606 516.755,65.022 516.623,62.101 C516.479,58.943 516.448,57.996 516.448,50 C516.448,42.003 516.479,41.056 516.623,37.899 C516.755,34.978 517.244,33.391 517.654,32.338 C518.197,30.938 518.846,29.942 519.894,28.894 C520.942,27.846 521.94,27.196 523.338,26.654 C524.393,26.244 525.979,25.756 528.898,25.623 C532.057,25.479 533.004,25.448 541,25.448 C548.997,25.448 549.943,25.479 553.102,25.623 C556.021,25.756 557.607,26.244 558.662,26.654 C560.06,27.196 561.058,27.846 562.106,28.894 C563.154,29.942 563.803,30.938 564.346,32.338 C564.756,33.391 565.244,34.978 565.378,37.899 C565.522,41.056 565.552,42.003 565.552,50 C565.552,57.996 565.522,58.943 565.378,62.101 M570.82,37.631 C570.674,34.438 570.167,32.258 569.425,30.349 C568.659,28.377 567.633,26.702 565.965,25.035 C564.297,23.368 562.623,22.342 560.652,21.575 C558.743,20.834 556.562,20.326 553.369,20.18 C550.169,20.033 549.148,20 541,20 C532.853,20 531.831,20.033 528.631,20.18 C525.438,20.326 523.257,20.834 521.349,21.575 C519.376,22.342 517.703,23.368 516.035,25.035 C514.368,26.702 513.342,28.377 512.574,30.349 C511.834,32.258 511.326,34.438 511.181,37.631 C511.035,40.831 511,41.851 511,50 C511,58.147 511.035,59.17 511.181,62.369 C511.326,65.562 511.834,67.743 512.574,69.651 C513.342,71.625 514.368,73.296 516.035,74.965 C517.703,76.634 519.376,77.658 521.349,78.425 C523.257,79.167 525.438,79.673 528.631,79.82 C531.831,79.965 532.853,80.001 541,80.001 C549.148,80.001 550.169,79.965 553.369,79.82 C556.562,79.673 558.743,79.167 560.652,78.425 C562.623,77.658 564.297,76.634 565.965,74.965 C567.633,73.296 568.659,71.625 569.425,69.651 C570.167,67.743 570.674,65.562 570.82,62.369 C570.966,59.17 571,58.147 571,50 C571,41.851 570.966,40.831 570.82,37.631"></path></g></g></g></svg></div><div style="padding-top: 8px;"> <div style=" color:#3897f0; font-family:Arial,sans-serif; font-size:14px; font-style:normal; font-weight:550; line-height:18px;">View this post on Instagram</div></div><div style="padding: 12.5% 0;"></div> <div style="display: flex; flex-direction: row; margin-bottom: 14px; align-items: center;"><div> <div style="background-color: #F4F4F4; border-radius: 50%; height: 12.5px; width: 12.5px; transform: translateX(0px) translateY(7px);"></div> <div style="background-color: #F4F4F4; height: 12.5px; transform: rotate(-45deg) translateX(3px) translateY(1px); width: 12.5px; flex-grow: 0; margin-right: 14px; margin-left: 2px;"></div> <div style="background-color: #F4F4F4; border-radius: 50%; height: 12.5px; width: 12.5px; transform: translateX(9px) translateY(-18px);"></div></div><div style="margin-left: 8px;"> <div style=" background-color: #F4F4F4; border-radius: 50%; flex-grow: 0; height: 20px; width: 20px;"></div> <div style=" width: 0; height: 0; border-top: 2px solid transparent; border-left: 6px solid #f4f4f4; border-bottom: 2px solid transparent; transform: translateX(16px) translateY(-4px) rotate(30deg)"></div></div><div style="margin-left: auto;"> <div style=" width: 0px; border-top: 8px solid #F4F4F4; border-right: 8px solid transparent; transform: translateY(16px);"></div> <div style=" background-color: #F4F4F4; flex-grow: 0; height: 12px; width: 16px; transform: translateY(-4px);"></div> <div style=" width: 0; height: 0; border-top: 8px solid #F4F4F4; border-left: 8px solid transparent; transform: translateY(-4px) translateX(8px);"></div></div></div> <div style="display: flex; flex-direction: column; flex-grow: 1; justify-content: center; margin-bottom: 24px;"> <div style=" background-color: #F4F4F4; border-radius: 4px; flex-grow: 0; height: 14px; margin-bottom: 6px; width: 224px;"></div> <div style=" background-color: #F4F4F4; border-radius: 4px; flex-grow: 0; height: 14px; width: 144px;"></div></div></a><p style=" color:#c9c8cd; font-family:Arial,sans-serif; font-size:14px; line-height:17px; margin-bottom:0; margin-top:8px; overflow:hidden; padding:8px 0 7px; text-align:center; text-overflow:ellipsis; white-space:nowrap;"><a href="https://www.instagram.com/p/CVYPb1msbRv/?utm_source=ig_embed&amp;utm_campaign=loading" style=" color:#c9c8cd; font-family:Arial,sans-serif; font-size:14px; font-style:normal; font-weight:normal; line-height:17px; text-decoration:none;" target="_blank" rel="noopener">A post shared by 💡Healthcare 3D Printing💡 (@3dheals)</a></p></div></blockquote> <script async="" src="//www.instagram.com/embed.js"></script>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph" id="h-jenny-ben-please-tell-us-a-little-about-you"><strong>Jenny: </strong>Ben, please tell us a little about you.</p>



<p class="wp-block-paragraph" id="h-ben-i-am-an-experienced-medtech-executive-developer-and-entrepreneur-i-have-been-a-researcher-and-now-a-product-developer-for-3d-printed-medical-devices-since-2011-i-have-successfully-lead-early-stage-medical-device-companies-since-2016"><span style="font-weight: 400;"><strong>Ben:&nbsp;</strong></span>I am an experienced medtech executive, developer, and entrepreneur. I have been a researcher and now a product developer for 3D printed medical devices since 2011. I have successfully led early-stage medical device companies since 2016.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny: </strong>Where are you from and what are you working on?&nbsp;</p>



<p class="wp-block-paragraph"><strong>Ben:</strong>&nbsp;I grew up in Northern Virginia. I came to DC in 2009 to study at George Washington University, in Grace Zhang’s tissue engineering lab. When I founded my company in 2016, we stayed in DC to continue a research relationship with GWU and to pursue a collaboration with Children’s National Medical Center. My company&nbsp;<a href="http://www.nanochon.com/" target="_blank" rel="noreferrer noopener">Nanochon</a>&nbsp;is developing a 3D printed porous and flexible implant for regenerating damaged cartilage in the knee. We were successful with securing essential development grants, and an SBIR from the National Science Foundation, and we just closed a $2M seed round to continue commercializing the technology.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny: </strong>What made you decide to become a 3DHEALS community manager?</p>



<p class="wp-block-paragraph"><strong>Ben:</strong>&nbsp;I have always had a passion for 3D printing, and all the unique benefits it can bring to healthcare. I first came into contact with 3DHeals at a conference in Washington DC and was impressed by the experience and passion displayed by the members I met. That motivated me to get more involved and made me want to share this important community with others.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny:</strong> What do you think of innovations in healthcare 3D printing or bioprinting? What do you hope to see in the next five years? 10 years?</p>



<p class="wp-block-paragraph"><strong>Ben:</strong>&nbsp;I think great progress has been made in the last 10 years, and there have been impressive examples of highly controlled, cell-supporting small-scale structures. I think improving speed and accuracy so these delicate small-scale structures can be produced throughout a large-scale implantable tissue is key. My hope is that new/cutting edge printing technology will be used to print new, biocompatible materials, at greater speeds and volumes.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny:</strong> If you have done 3D printing before, what have you made/designed?&nbsp;</p>



<p class="wp-block-paragraph"><strong>Ben:</strong>&nbsp;My company is developing an implant for cartilage repair. It is a disk-like structure roughly the size of a coin, with the thickness of cartilage, designed to re-surface areas of a joint that has lost or damaged cartilage tissue. In my past research, I also used 3D printing to design and print structures for bone and micro-vascular tissues.<br><br><br><br></p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny: </strong>Most of our community managers are entrepreneurial and adventurous, what risks/adventures have you taken that you’d like to share with us?</p>



<p class="wp-block-paragraph"><strong>Ben:</strong>&nbsp;Starting my company! I think especially in the “long-term” implantable device space, there is a lot of clinical and financial risk, and it takes a lot of work before such companies are truly “fundable.” We had great early success with grants and&nbsp;<a href="https://www.sbir.gov/" target="_blank" rel="noreferrer noopener">SBIR</a>&nbsp;funding and just closed our first institutional round. My hope is that we can continue to grow and get the funds we need, I think our technology really shines in this space, where there have been many failed attempts,and there is a clear need clinically, I will continue to share my vision with those who have the resources to help us get to the next level.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny: </strong>Who would you like to find and include in the 3DHEALS community you are building?</p>



<p class="wp-block-paragraph"><strong>Ben:</strong>&nbsp;Other young researchers and entrepreneurs like I was, who need talented and resourceful people to take an interest in them, guide them, and help them succeed. On the other side, I have loved to see the involvement of key industry players in medical 3D printing, and want to see 3D HEALS continue to be a place that can bring entrepreneurs and industry together.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny:</strong> What would you like to accomplish with this new 3DHEALS community in the future?</p>



<p class="wp-block-paragraph"><strong>Ben:</strong>&nbsp;I think building pipelines for 3D printed technology to get from the lab to the clinic is a must. I would love to see 3D HEALS become the premier networking event for doctors, researchers, investors, and strategic partners in the 3D printing space.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny: </strong>What do you think about the innovation environment (for health tech or for general technology) in your city?</p>



<p class="wp-block-paragraph"><strong>Ben:</strong>&nbsp;I have been impressed over the last 3-4 years. DC was lacking, when it comes to investors and financing interested in medical devices. But lately, there has been greatly renewed interest, supported largely by talented researchers and clinicains founding companies and staying in the area. I believe there is now a base of high value companies that is attracting investment and resources. </p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny: </strong>What are you most proud of about your city?</p>



<p class="wp-block-paragraph"><strong>Ben:</strong>&nbsp;I think DC has made great strides in the last 15-20 years to really become a vibrant and livable community.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny: </strong>What are you most proud of about the innovation community in your city?</p>



<p class="wp-block-paragraph"><strong>Ben:</strong>&nbsp;DC continues to be a cradle for generating great ideas, and the infrastructure to take them further is growing, supported by investors, industry, and world-class universities.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny: </strong>What do you think are the top priorities in healthcare innovations for your city/community?</p>



<p class="wp-block-paragraph"><strong>Ben:</strong> Improving patient outcomes through better clinical management and treatment efficiency. DC has in fact been a testbed for companies large and small focused on community health initiatives.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny: </strong>What do you hope to accomplish through your role as the 3DHEALS community manager?</p>



<p class="wp-block-paragraph"><strong>Ben:</strong>&nbsp;I want to do what I can to help&nbsp; DC continue to grow and evolve its innovation ecosystem.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny: </strong>What do you do for fun?</p>



<p class="wp-block-paragraph"><strong>Ben: </strong>Before the pandemic, I enjoyed going to shows and concerts. But I have become sort of outdoorsy, enjoying hiking, camping, and other outdoor adventures. I also love to cook and travel. </p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny: </strong>Anything else?</p>



<p class="wp-block-paragraph"><strong>Ben:</strong>&nbsp;I can’t wait to help the DC 3DHEALS community thrive!</p>



<p class="wp-block-paragraph"></p>



<h2 class="wp-block-heading" id="h-related-articles">Related Articles: </h2>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><a href="https://3dheals.com/interview-with-prof-huang-dejian-kosmodehealth" target="_blank" rel="noreferrer noopener">Interview with Prof. Huang Dejian: CEO, Kosmodehealth</a></p>



<p class="wp-block-paragraph"><a href="https://3dheals.com/interview-with-dr-wei-jiang-goh-crafthealth" target="_blank" rel="noreferrer noopener">Interview with Dr. Wei Jiang GOH: CEO, Crafthealth</a></p>



<p class="wp-block-paragraph"><a href="https://3dheals.com/interview-with-amrish-nair-biorithm" target="_blank" rel="noreferrer noopener">Interview with Amrish Nair: CEO, BIORITHM</a></p>



<p class="wp-block-paragraph">Interview: Adam Jakus, Chief Technology of DimensionInx</p>



<p class="wp-block-paragraph"><a href="https://3dheals.com/bone-grafts-inducing-bone-regeneration-with-3d-printed-porosity" target="_blank" rel="noreferrer noopener">Bone Grafts: Inducing Bone Regeneration with 3D Printed Porosity</a></p>



<p class="wp-block-paragraph"><a href="https://3dheals.com/courses/3dheals2020-summit-recordings/lessons/3dheals2020-session-17-biofab-ecosystem" target="_blank" rel="noreferrer noopener">3DHEALS2020 Session 17. Biofabrication Ecosystem</a></p>



<p class="wp-block-paragraph"><a href="https://3dheals.com/interview-with-adam-clark-tangible-solutions" target="_blank" rel="noreferrer noopener">Interview with Adam Clark, Tangible Solutions</a></p>



<p class="wp-block-paragraph"><a href="https://3dheals.com/bio-fabrication-techniques-for-bone-and-cartilage-tissue-regeneration" target="_blank" rel="noreferrer noopener">Bio Fabrication Techniques for Bone and Cartilage Tissue Regeneration</a></p>



<p class="wp-block-paragraph">Interview: Professor Adam Feinberg, Carnegie Mellon University, CTO and co-founder FluidForm</p>
<p>The post <a href="https://3dheals.com/interview-benjamin-holmes-washington-dc/">Interview: Dr. Benjamin Holmes, CEO Nanochon</a> appeared first on <a href="https://3dheals.com">3DHeals</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://3dheals.com/interview-benjamin-holmes-washington-dc/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Interview: Dr. Albert Woo, Brown University</title>
		<link>https://3dheals.com/interview-dr-albert-woo/</link>
					<comments>https://3dheals.com/interview-dr-albert-woo/#comments</comments>
		
		<dc:creator><![CDATA[Jenny Chen, M.D.]]></dc:creator>
		<pubDate>Wed, 06 Oct 2021 04:43:00 +0000</pubDate>
				<category><![CDATA[Blog]]></category>
		<category><![CDATA[Influencer Interviews]]></category>
		<category><![CDATA[3D-printing]]></category>
		<category><![CDATA[additive manufacture]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[healthcare]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[interview]]></category>
		<category><![CDATA[plastic surgery]]></category>
		<category><![CDATA[Technology]]></category>
		<guid isPermaLink="false">https://3dheals.com/?p=9279</guid>

					<description><![CDATA[<p><a href="https://3dheals.com">3DHeals - Discover 3D Bioprinting and Healthcare Innovations</a></p>
<p> It was probably during my craniofacial surgery fellowship over a decade ago that I first encountered a 3D printed surgical model. I was amazed at the incredible detail that was present in these models and the fact that they could be sterilized for use in the operating room. Plastic surgeons have been using these types of models for decades now but the incredible power of this technology never ceases to fascinate me.<br />
 However, the biggest impact to me came when obtained our first grant to purchase a professional grade 3D printer in 2015. This dramatically affected my practice. For the first time, I had control over the 3D models that we printed without going through the multiple steps of ordering it through a vendor. We were able to make models quickly, some printed overnight for surgery the next day, making this technology available even for urgent surgical cases.</p>
<p>The post <a href="https://3dheals.com/interview-dr-albert-woo/">Interview: Dr. Albert Woo, Brown University</a> appeared first on <a href="https://3dheals.com">3DHeals</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><a href="https://3dheals.com">3DHeals - Discover 3D Bioprinting and Healthcare Innovations</a></p>

<div class="wp-block-image"><figure class="alignleft"><a href="https://3dheals.com/wp-content/uploads/2018/05/Albert-Woo.jpg"><img fetchpriority="high" decoding="async" width="214" height="300" src="https://3dheals.com/wp-content/uploads/2018/05/Albert-Woo-214x300.jpg" alt="" class="wp-image-9225" srcset="https://3dheals.com/wp-content/uploads/2018/05/Albert-Woo-214x300.jpg 214w, https://3dheals.com/wp-content/uploads/2018/05/Albert-Woo-447x626.jpg 447w, https://3dheals.com/wp-content/uploads/2018/05/Albert-Woo-768x1075.jpg 768w, https://3dheals.com/wp-content/uploads/2018/05/Albert-Woo-731x1024.jpg 731w, https://3dheals.com/wp-content/uploads/2018/05/Albert-Woo-510x714.jpg 510w, https://3dheals.com/wp-content/uploads/2018/05/Albert-Woo.jpg 660w" sizes="(max-width: 214px) 100vw, 214px" /></a></figure></div>



<p class="p1 wp-block-paragraph"><a href="https://www.linkedin.com/in/woo-albert-120265b6/">Albert S. Woo,</a>&nbsp;FACS is a board-certified plastic and reconstructive surgeon who specializes in the treatment of cleft and craniofacial anomalies. This work has led to a particular interest in three-dimensional imaging and printing of complex surgical models. He is an Associate Professor of Surgery, Pediatrics, and Neurosurgery at The Warren Alpert Medical School of Brown University and serves as the Chief of the Division of Pediatric Plastic Surgery, Director of the Cleft and Craniofacial Center at Hasbro Children’s Hospital, and Director of the new Lifespan 3D Printing Laboratory.</p>



<p class="p1 wp-block-paragraph">Besides medical 3D printing, Dr. Woo’s clinical interests include the surgical treatment of patients with craniosynostosis, complex and syndromic craniofacial abnormalities, and cleft deformities. In particular, he is internationally recognized as an expert in cleft palate repair, after having developed a new surgical technique for this procedure. He is also nationally recognized for his expertise in Endoscopic Craniosynostosis Surgery, with numerous papers and national presentations on the subject. With more than 60 peer-reviewed publications, numerous chapters and a book, Dr. Woo remains committed not only to clinical excellence but also to advancing research in the treatment of craniofacial anomalies.</p>



<p class="p1 wp-block-paragraph">Dr. Woo currently is a member of numerous societies including the American College of Surgeons, the American Society of Maxillofacial Surgeons, the American Cleft Palate-Craniofacial Association, the American Association of Plastic Surgeons, and the American Society of Plastic Surgeons. He is the recipient of numerous awards, including recognition by Best Doctors in America since 2011 and Castle Connolly’s Top Doctors. Dr. Woo recently co-founded a startup, <a href="https://sites.google.com/view/implant3dinc" target="_blank" rel="noreferrer noopener"><strong>Implant3D</strong></a>. </p>



<h3 class="wp-block-heading" id="h-dr-woo-will-be-presenting-at-our-upcoming-3d-printing-in-hospital-webinar"><a href="https://3dheals.com/3d-printing-in-hospitals" target="_blank" rel="noreferrer noopener"><strong><span style="color: #cc145f;">Dr. Woo will be presenting at our upcoming 3D Printing in Hospital webinar</span></strong></a></h3>



<div class="wp-block-image"><figure class="aligncenter size-large is-resized"><img decoding="async" src="https://3dheals.com/wp-content/uploads/2020/04/3dheals2020-heart2.png" alt="" class="wp-image-22743" width="258" height="258" srcset="https://3dheals.com/wp-content/uploads/2020/04/3dheals2020-heart2.png 500w, https://3dheals.com/wp-content/uploads/2020/04/3dheals2020-heart2-245x245.png 245w, https://3dheals.com/wp-content/uploads/2020/04/3dheals2020-heart2-100x100.png 100w, https://3dheals.com/wp-content/uploads/2020/04/3dheals2020-heart2-447x447.png 447w, https://3dheals.com/wp-content/uploads/2020/04/3dheals2020-heart2-150x150.png 150w, https://3dheals.com/wp-content/uploads/2020/04/3dheals2020-heart2-300x300.png 300w, https://3dheals.com/wp-content/uploads/2020/04/3dheals2020-heart2-250x250.png 250w" sizes="(max-width: 258px) 100vw, 258px" /></figure></div>



<div id="buzzsprout-player-3650866"></div>
<script src="https://www.buzzsprout.com/1015072/3650866-interview-with-albert-woo-chief-of-pediatric-plastic-surgery-and-3d-printing-lab-brown-university.js?container_id=buzzsprout-player-3650866&amp;player=small" type="text/javascript" charset="utf-8"></script>



<p class="wp-block-paragraph"><strong>Jenny: When was the first encounter you had with 3D printing? What was that experience like? What were you thinking at that moment?</strong></p>



<p class="wp-block-paragraph"><br><span style="font-weight: 400;"><strong><span style="color: #cc145f;">Albert:</span> </strong>It was probably during my craniofacial surgery fellowship over a decade ago that I first encountered a 3D printed surgical model. I was amazed at the incredible detail that was present in these models and the fact that they could be sterilized for use in the operating room. Plastic surgeons have been using these types of models for decades now but the incredible power of this technology never ceases to fascinate me.</span><br>However, the biggest impact to me came when I obtained our first grant to purchase a professional-grade 3D printer in 2015. This dramatically affected my practice. For the first time, I had control over the 3D models that we printed without going through the multiple steps of ordering it through a vendor. We were able to make models quickly, some printed overnight for surgery the next day, making this technology available even for urgent surgical cases.</p>



<p class="wp-block-paragraph"><br><strong>Jenny: What inspired you to start your journey in 3D printing?</strong></p>



<p class="wp-block-paragraph"><br><span style="font-weight: 400;"><span style="color: #cc145f;"><strong>Albert:</strong> </span>As with most things in life, it was pure luck. As I began my career, I inherited a 3D imaging lab started by Dr. Jeffrey Marsh, who is credited (along with Dr. Michael Vannier) with having developed the technology for 3D modeling of 2D CT scans. As we pursued this work, I happened to meet a bioengineer who was interested in 3D printing. Honestly, I hadn’t thought much about printing until then but it was a natural leap in our research. We decided to submit a joint grant proposal for a professional-grade 3D printer, which got me started on the exciting path of looking at the use of 3D printing in medical care. </span></p>



<figure class="wp-block-embed is-type-video is-provider-vimeo wp-block-embed-vimeo"><div class="wp-block-embed__wrapper">
<iframe title="Interview with Albert Woo, Chief of Pediatric Plastic Surgery and 3D Printing Lab, Brown University" src="https://player.vimeo.com/video/415695872?dnt=1&amp;app_id=122963" width="500" height="313" frameborder="0" allow="autoplay; fullscreen; picture-in-picture; clipboard-write"></iframe>
</div></figure>



<p class="wp-block-paragraph"><br><strong>Jenny: Who inspired you the most along this journey in 3D printing?</strong></p>



<p class="wp-block-paragraph"><br><span style="font-weight: 400;"><span style="color: #cc145f;"><strong>Albert:</strong> </span>Really, it is a number of people. I cannot laud the work of Dr. Jeffrey Marsh enough, who was a pioneer in the field of 3D craniofacial imaging. I would like the opportunity to carry on some of his work to stand on the shoulders of giants. Beyond this, I have to give credit to my friend and colleague in pediatric cardiology, <a href="https://3dheals.com/the-heart-of-the-matter-interview-with-dr-shafkat-anwar-ucsf" target="_blank" rel="noreferrer noopener">Dr. Shafkat Anwar</a>. Until we had met, I largely focused on pursuing my own clinical interests in 3D printing and craniofacial imaging. However, he helped to really widen my horizons, pushing me out of my silo to start really examining what 3D printing can do in the field of medicine overall.</span></p>



<p class="wp-block-paragraph"><br><strong>Jenny: What motivates you the most for your work? </strong></p>



<p class="wp-block-paragraph"><br><span style="font-weight: 400;"><span style="color: #cc145f;"><strong>Albert:</strong> </span>This answer is easy. I love what I do and I have fun doing it. It’s even made more special when you realize that the work being performed has direct implications for patient care. Not only is some of the modeling that we do is “cool,” but it has s real impact on people’s lives. What can be better?</span></p>



<p class="wp-block-paragraph"><br><strong>Jenny: What is/are the biggest obstacle(s) in your line of work? If you have conquered them, what were your solutions? </strong></p>



<p class="wp-block-paragraph"><br><span style="font-weight: 400;"><span style="color: #cc145f;"><strong>Albert:</strong></span> One of the greatest obstacles is simply obtaining the support to do the work that we do in 3D printing. Printers, materials, software, lab space, employees, time, and training all require funding and support. Unfortunately, the value of this technology isn’t always readily apparent to the folks who focus on the financial statements. To help, it has been critical to obtaining buy-in from other clinicians who have benefited from our 3D models. It has also been useful to sit down with administrators to demonstrate the direct impact that our work has on the care of patients in the hospital. </span></p>



<p class="wp-block-paragraph"><br><strong>Jenny: What do you think is (are) the biggest challenge(s) in 3D Printing? What do you think the potential solution(s) is (are)?</strong></p>



<p class="wp-block-paragraph"><br><span style="font-weight: 400;"><span style="color: #cc145f;"><strong>Albert:</strong></span> 3D printing in medicine is still a fairly nascent industry and it seems like we are constantly pushing the boundaries of what our software or machines are capable of doing. One of the most notable issues is the disconnect between software and hardware. While CAD-CAM technologies are readily available in manufacturing, the medical domain seems to have far fewer options for high-level</span> modeling of DICOM data, particularly if you are utilizing multiple colors and texture maps. I’m sure that these will come with time but there is still a long way to go before medical 3D printing is truly “plug and play.”<br>Jenny: If you are granted three wishes by a higher being, what would they be? &nbsp;<br>Albert: If I could only add another few hours each day and extra days to the week, my life would be perfect! Beyond this, I would love to know everything about 3D modeling and be able to easily impart this knowledge to the world. I think venues like 3DHeals are an excellent avenue to begin an open dialogue so that we can all learn from each other, sharing ideas and techniques, thereby advancing the field of 3D printing in medicine as a whole. <br>Jenny: What advice would you give to a smart driven college student in the “real world”? What bad advice you heard should they ignore? <br>Albert: Learn everything you can and don’t limit your fund of knowledge. Explore your creative and artistic sides at the same time that you look into science and technology. I see 3D printing as a canvas to draw upon. The masters will not only have the fundamental skills to use the printer but also the imagination to draw out the best from the technology. Most importantly, don’t get disappointed with failure,<span style="font-weight: 400;"> and don’t give up. </span></p>



<p class="wp-block-paragraph"><br><strong>Jenny: If you could have a giant billboard to promote a message to millions and even billions of people in our community (i.e. healthcare 3D printing and bio-fabrication), what message would that be? </strong></p>



<p class="wp-block-paragraph"><br><span style="font-weight: 400;"><span style="color: #cc145f;"><strong>Albert:</strong></span> Collaborate and open your minds. And leave your egos at the door.</span></p>



<p class="wp-block-paragraph"><br><strong>Jenny: What were/was the best/worst investment you made in 3D printing? </strong></p>



<p class="wp-block-paragraph"><br><span style="font-weight: 400;"><span style="color: #cc145f;"><strong>Albert:</strong></span> I had to learn that I couldn’t do all of this on my own. So really the best thing I did was to hire our 3D coordinator to manage the specifics of the program. As a corollary, the worst thing was to try to do it all myself. This simply led to confusion, delays, and aggravation.</span></p>



<p class="wp-block-paragraph"><br><strong>Jenny: What was/is the biggest risk you took in your career?</strong></p>



<p class="wp-block-paragraph"><br><span style="font-weight: 400;"><span style="color: #cc145f;"><strong>Albert:</strong> </span>I had a great practice at Washington University in St. Louis with a burgeoning 3D program that was just taking off. It was difficult to decide to move to my alma mater, Brown University/Rhode Island Hospital, and start all over again &#8212; building a new program from scratch. But it was the right thing to do and I have never regretted that decision. </span></p>



<p class="wp-block-paragraph"><br><strong>Jenny: What do you enjoy in your spare time? What are you passionate about outside of your work/3d printing?</strong></p>



<p class="wp-block-paragraph"><br><span style="font-weight: 400;"><span style="color: #cc145f;"><strong>Albert:</strong> </span>Family comes first. So I do my best to spend as much time with the family as possible.</span></p>



<p class="wp-block-paragraph"><br><strong>Jenny: What is your favorite quote? Why?</strong></p>



<p class="wp-block-paragraph"><br><span style="font-weight: 400;"><span style="color: #cc145f;"><strong>Albert:</strong> </span>“Chance favors the prepared mind.” &#8211; Louis Pasteur</span><br><span style="font-weight: 400;">Insight and game-changing developments just don’t happen. They are the result of preparation, thought, and previous effort. Even when random opportunities present themselves, some will be better prepared to take advantage of fortuitous events.</span></p>



<p class="wp-block-paragraph"><br><strong>Jenny: What does the word “3DHEALS” mean to you? &nbsp;=)</strong></p>



<p class="wp-block-paragraph"><br><span style="font-weight: 400;"><span style="color: #cc145f;"><strong>Albert:</strong> </span>3D printing (and additive manufacturing as a whole) has incredible potential to change the world. We would love to use this new technology to improve healthcare overall</span>.</p>



<p class="wp-block-paragraph"></p>



<h2 class="wp-block-heading" id="h-related-articles">Related Articles: </h2>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><a rel="noreferrer noopener" href="https://3dheals.com/challenges-facing-3d-printing-in-reconstructive-surgeries" target="_blank">Challenges Facing 3D Printing in Reconstructive Surgeries</a></p>



<p class="wp-block-paragraph"><a rel="noreferrer noopener" href="https://3dheals.com/webinar-recording-can-3d-printing-save-us-from-covid19-crisis" target="_blank">Webinar Recording: Can 3D Printing Save Us From COVID19 Crisis?</a></p>



<p class="wp-block-paragraph"><a rel="noreferrer noopener" href="https://3dheals.com/from-cleft-palate-to-bioprinted-lungs-reality-dreams-ambition" target="_blank">3DHEALS Boston 2018: From Cleft Palate to Bioprinted Lungs, Reality, Dreams, and Ambition</a></p>



<p class="wp-block-paragraph"><a rel="noreferrer noopener" href="https://3dheals.com/interview-with-roger-kuan-intellectual-property-concern-for-healthcare-3d-printing" target="_blank">Interview with Roger Kuan, Intellectual Property Concern for Healthcare 3D Printing</a></p>



<p class="wp-block-paragraph"><a href="https://3dheals.com/interview-with-shannon-walters-stanford-3d-lab-video" target="_blank" rel="noreferrer noopener">Interview with Shannon Walters, Stanford 3D Lab (Video)</a></p>
<p>The post <a href="https://3dheals.com/interview-dr-albert-woo/">Interview: Dr. Albert Woo, Brown University</a> appeared first on <a href="https://3dheals.com">3DHeals</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://3dheals.com/interview-dr-albert-woo/feed/</wfw:commentRss>
			<slash:comments>1</slash:comments>
		
		
			</item>
		<item>
		<title>3D Printing in Hospitals (Guide): Acknowledgement, References</title>
		<link>https://3dheals.com/reference/</link>
					<comments>https://3dheals.com/reference/#respond</comments>
		
		<dc:creator><![CDATA[Jenny Chen, M.D.]]></dc:creator>
		<pubDate>Sat, 28 Nov 2020 07:08:00 +0000</pubDate>
				<category><![CDATA[Blog]]></category>
		<category><![CDATA[Healthcare 3D Printing Guide]]></category>
		<category><![CDATA[3D-printing]]></category>
		<category><![CDATA[additive manufacture]]></category>
		<category><![CDATA[amazon]]></category>
		<category><![CDATA[Biomechanical Testing Facility]]></category>
		<category><![CDATA[bioprinting]]></category>
		<category><![CDATA[book]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[healthcare]]></category>
		<category><![CDATA[Ideas to Implementation]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[medical]]></category>
		<category><![CDATA[Mimics]]></category>
		<category><![CDATA[reimbursement]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[surgical planning]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[whitepaper]]></category>
		<guid isPermaLink="false">https://3dheals.com/?p=1464</guid>

					<description><![CDATA[<p><a href="https://3dheals.com">3DHeals - Discover 3D Bioprinting and Healthcare Innovations</a></p>
<p>In 2016, when I co-authored the first edition of " A Roadmap from Idea to Implementation: 3D Printing for Pre-Surgical Application: Operational Management for 3D Printing in Surgery", focusing on a systematic thinking process to address these questions by evaluating components of operational management with Michelle Gabriel. However, selling a book is not going to accelerate adaption, instead, I decided to publish this book as a regularly updated online version of 3DHEALS Guide in five digestible parts, focusing on and adding new information from field experts from all over the world to provide a foundation to any early adapters. The first time I learned about 3D printing (a.k.a. additive manufacturing ) for pre-surgical planning was in 2012 during RSNA (Radiological Society of North America) in Chicago. As a small box containing pieces of a 3D-printed heart from a pediatric patient was passed around the conference room, I could tell that the room stopped breathing. For me, it was a sensational moment as a radiologist and as a healthcare provider. Having a patient’s disease in three-dimension in my hands was unimaginable. I immediately wanted to learn more about the technology and how I, as a radiologist, could use it to help my clinical colleagues. However, to me, the road to implementation was not simple and almost obscure.  The barrier to entry for such technology seems to require one to be a combination of a designer, a mechanical engineer, and a software developer, and lastly a healthcare provider. </p>
<p>The post <a href="https://3dheals.com/reference/">3D Printing in Hospitals (Guide): Acknowledgement, References</a> appeared first on <a href="https://3dheals.com">3DHeals</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><a href="https://3dheals.com">3DHeals - Discover 3D Bioprinting and Healthcare Innovations</a></p>

<p class="wp-block-paragraph">In 2016, when I co-authored the first edition of &#8221; <a rel="noreferrer noopener" href="https://www.amazon.com/Roadmap-Idea-Implementation-Pre-Surgical-Application-ebook/dp/B01M1I66D4/ref=sr_1_2?keywords=idea+to+implementation+3d+printing&amp;qid=1638996389&amp;sr=8-2" target="_blank">A Roadmap from Idea to Implementation: 3D Printing for Pre-Surgical Application: Operational Management for 3D Printing in Surgery</a>&#8220;, focusing on&nbsp;<a rel="noreferrer noopener" href="https://www.amazon.com/Roadmap-Idea-Implementation-Pre-Surgical-Application-ebook/dp/B01M1I66D4/ref=sr_1_2?dchild=1&amp;keywords=idea+to+implementation+3d+printing&amp;qid=1601755550&amp;sr=8-2" target="_blank">a systematic thinking process to address these questions by evaluating components of operational management</a>&nbsp;with&nbsp;<a href="https://www.linkedin.com/in/mwgabriel/" target="_blank" rel="noreferrer noopener">Michelle Gabriel</a>. However, selling a book is not going to accelerate adaption, instead, I decided to publish this book as a regularly updated online version of <a href="https://3dheals.com/category/healthcare-3d-printing-guide/" target="_blank" rel="noreferrer noopener">3DHEALS Guide </a>in five digestible parts, focusing on and adding new information from field experts from all over the world to provide a foundation to any early adapters. </p>



<p class="wp-block-paragraph">The first time I learned about 3D printing (a.k.a. additive manufacturing ) for pre-surgical planning was in 2012 during RSNA (Radiological Society of North America) in Chicago. As a small box containing pieces of a 3D-printed heart from a pediatric patient was passed around the conference room, I could tell that the room stopped breathing. For me, it was a sensational moment as a radiologist and as a healthcare provider. Having a patient’s disease in three-dimension in my hands was unimaginable. I immediately wanted to learn more about the technology and how I, as a radiologist, could use it to help my clinical colleagues. However, to me, the road to implementation was not simple and almost obscure.&nbsp; The barrier to entry for such technology seems to require one to be a combination of a designer, a mechanical engineer, and a software developer, and lastly a healthcare provider.&nbsp;</p>



<p class="wp-block-paragraph">Not giving up, I started organizing meetings focusing on learning and discussing healthcare 3D printing solutions in San Francisco called 3DHEALS, hoping to create a <a href="https://3dheals.com/about/" target="_blank" rel="noreferrer noopener">community </a>composed of various disciplines to start to have more practical conversations to accelerate the adaptation of the technology.</p>



<p class="wp-block-paragraph">Michelle and I met at an after-work healthcare technology conference, and we instantly hit it off because of our complementary knowledge and interest in healthcare, operational management, 3D printing, and engineering. We are both fascinated with the complex process of integrating promising technologies into healthcare. On top of that, Michelle’s background in both operations management and material science and engineering, and mine in medicine and education add unique perspectives to this book.&nbsp;</p>



<p class="wp-block-paragraph">That said, we both are fully aware of our limitations in various aspects of the subject of 3D printed surgical planning and do not proclaim to be field experts. This post serves as part 7 of this Guide series to thank individuals and companies for their insights and relationship with us and publication reference. Since our Guides are regularly updated and our <a href="https://3dheals.com/courses/" target="_blank" rel="noreferrer noopener">conversations </a>with our ecosystem never stop, this page will be updated whenever our guides are updated when appropriate. </p>



<p class="wp-block-paragraph"></p>



<h2 class="wp-block-heading" id="h-now-on-demand">Now On Demand:</h2>



<figure class="wp-block-embed is-type-wp-embed is-provider-3-dheals wp-block-embed-3-dheals"><div class="wp-block-embed__wrapper">
<blockquote class="wp-embedded-content" data-secret="C6XKVqmYXw"><a href="https://3dheals.com/courses/3d-printing-in-hospitals/">3D Printing in Hospitals</a></blockquote><iframe loading="lazy" class="wp-embedded-content" sandbox="allow-scripts" security="restricted"  title="&#8220;3D Printing in Hospitals&#8221; &#8212; 3DHeals" src="https://3dheals.com/courses/3d-printing-in-hospitals/embed/#?secret=jWVOtgqvgj#?secret=C6XKVqmYXw" data-secret="C6XKVqmYXw" width="500" height="282" frameborder="0" marginwidth="0" marginheight="0" scrolling="no"></iframe>
</div></figure>



<ol class="wp-block-list" id="block-f6502ae5-498e-4a4e-a365-0d25eb63879e"><li><a rel="noreferrer noopener" href="https://3dheals.com/3d-printing-in-hospitals-a-beginners-guide" target="_blank">Introduction:&nbsp;&nbsp;What is operational management?</a></li><li><a rel="noreferrer noopener" href="https://3dheals.com/3d-printing-in-hospitals-a-beginners-guide" target="_blank">Technical Background</a></li><li><a href="https://3dheals.com/strategic-issues-of-3d-printing-in-hospitals-guide/" target="_blank" rel="noreferrer noopener">Strategic Issues</a></li><li><a href="https://3dheals.com/tactical-issues-3d-printing-in-hospital" target="_blank" rel="noreferrer noopener">Tactical Issues</a></li><li><a href="https://3dheals.com/financial-issues-of-3d-printing-in-hospitals-guide/" target="_blank" rel="noreferrer noopener">Financial Issues&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</a></li><li>Financial Worksheet<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></li><li><strong>Acknowledgments/References</strong></li></ol>



<p class="wp-block-paragraph"></p>



<h2 class="wp-block-heading"><strong>Acknowledgements:&nbsp;</strong></h2>



<p class="wp-block-paragraph">We would like to give special thanks and acknowledgment to the following individuals:&nbsp;</p>



<ul class="wp-block-list"><li>Dr. Parit Patel (Assistant professor of plastic and reconstructive surgery at Loyola Medicine)</li><li>Dr. Elliot Brown (Assistant professor of radiology and biomedical imaging at Yale University)</li><li>Dr. Jose Morey (Medical scientist with IBM Watson project, adjunct professor of radiology and biomedical imaging at the University of Virginia)</li><li>Mr. Glen Jett from Sutter Health for providing valuable financial insights.</li><li>Dr. Justin Ryan (Arizona State University Post-Doctoral Researcher, Phoenix Children’s Hospital Research Scientist) for providing valuable feedbacks and research on 3D printing for pediatric congenital heart cases.</li></ul>



<ul class="wp-block-list"><li>Dr. Justin Ryan  </li><li>Mr. Shannon Walter (Stanford School of Medicine, Manager of 3D and Quantitative Imaging Laboratory)</li><li>Mr. Chris Letrong (Stanford School of Medicine, 3D Technologist)</li><li>Dr. Ben Taragin (Children Hospital at Montefiore, Director of Pediatric Radiology)</li><li>Dr. Joaquim M. Farinhas (Neuroradiology, Montefiore Medical Center)</li><li>Materialse Inc.&nbsp;</li><li>Whitecloud Inc.&nbsp;</li><li>Stanford School of Medicine</li></ul>



<p class="wp-block-paragraph"></p>



<h2 class="wp-block-heading">References:</h2>



<ol class="wp-block-list"><li>Columbus L. 2015 roundup of 3D printing market forecasts and estimates. <a href="http://www.forbes.com/sites/louiscolumbus/2015/03/31/2015-roundup-of-3d-printing-market-forecasts-and-estimates/">http://www.forbes.com/sites/louiscolumbus/2015/03/31/2015-roundup-of-3d-printing-market-forecasts-and-estimates/</a>. Published March 31, 2015.</li><li>Chen HJ, Gabriel M. Healthcare 3D printing in academia. <em>3D </em> https://3dheals.com/healthcare-3d-printing-in-academia/. Published October 1, 2015.</li><li>Friedman T, Michalski M, Goodman TR, Elliot Brown. 3D printing from diagnostic images: a radiologist’s primer with an emphasis on musculoskeletal imaging—putting the 3D printing of pathology into the hands of every physician. <em>Skeletal Radiology</em>, 1–15. <a href="http://doi.org/10.1007/s00256-015-2282-6">http://doi.org/10.1007/s00256-015-2282-6</a>. Published November 23, 2015.</li><li>Koleilat I, Jaeggli M, Ewing JA, et al. Interobserver variability in physician-modified endograft planning by comparison with a three-dimensional printed aortic model. <em>Journal of Vascular Surgery</em>, 1–8. <a href="http://doi.org/10.1016/j.jvs.2015.09.044">http://doi.org/10.1016/j.jvs.2015.09.044</a>. Published June 17, 2015.</li><li>Vaquerizo B, Theriault-Lauzier P, Piazza N. Percutaneous Transcatheter Mitral Valve Replacement: Patient-specific Three-dimensional Computer-based Heart Model and Prototyping. <em>Revista Española De Cardiología</em> (English Edition), 1–9. <a href="http://doi.org/10.1016/j.rec.2015.08.005">http://doi.org/10.1016/j.rec.2015.08.005</a>.</li><li>Giannopoulos AA, Chepelev L, Sheikh A, et al. 3D printed ventricular septal defect patch: a primer for the 2015 Radiological Society of North America (RSNA) hands-on course in 3D printing. <em>3D Printing in Medicine</em>, 1–20. <a href="http://doi.org/10.1186/s41205-015-0002-4">http://doi.org/10.1186/s41205-015-0002-4</a>.</li><li>Cai T, Rybicki FJ, Giannopoulos AA, et al. The residual STL volume as a metric to evaluate accuracy and reproducibility of anatomic models for 3D printing: application in the validation of 3D-printable models of maxillofacial bone from reduced radiation dose CT images. <em>3D Printing in Medicine</em>, 1–9. <a href="http://doi.org/10.1186/s41205-015-0003-3">http://doi.org/10.1186/s41205-015-0003-3</a>.</li><li>Rybicki FJ. 3D Printing in Medicine: an introductory message from the Editor-in-Chief. <em>3D Printing in Medicine</em>, 1–1. <a href="http://doi.org/10.1186/s41205-015-0001-5">http://doi.org/10.1186/s41205-015-0001-5</a>.</li><li>VanKoevering KK, Morrison RJ, Prabhu SP, et al. Antenatal Three-Dimensional Printing of Aberrant Facial Anatomy. <em>Pediatrics</em>, 136(5), e1382–e1385. <a href="http://doi.org/10.1542/peds.2015-1062">http://doi.org/10.1542/peds.2015-1062</a>.</li><li>Dickinson KJ, Matsumoto J, Cassivi SD, et al. Individualizing Management of Complex Esophageal Pathology Using Three-Dimensional Printed Models. <em>The Annals of Thoracic Surgery</em>, 100(2), 692–697. <a href="http://doi.org/10.1016/j.athoracsur.2015.03.115">http://doi.org/10.1016/j.athoracsur.2015.03.115</a>.</li><li>Itagaki MW. Using 3D printed models for planning and guidance during endovascular intervention: a technical advance. <em>Diagnostic and Interventional Radiology</em>, 21(4), 338–341. <a href="http://doi.org/10.5152/dir.2015.14469">http://doi.org/10.5152/dir.2015.14469</a>.</li><li>Tai BL, Wang AC, Joseph JR, et al. A physical simulator for endoscopic endonasal drilling techniques: technical note. <em>Journal of Neurosurgery</em>, 1–6. <a href="http://doi.org/10.3171/2015.3.JNS1552">http://doi.org/10.3171/2015.3.JNS1552</a>.</li><li>Weinstock P, Prabhu SP, Flynn K, et al. Optimizing cerebrovascular surgical and endovascular procedures in children via personalized 3D printing. <em>Journal of Neurosurgery: Pediatrics</em>, 1–6. <a href="http://doi.org/10.3171/2015.3.PEDS14677">http://doi.org/10.3171/2015.3.PEDS14677</a>.</li><li>Grant GT, Liacouras P, Santiago GF, et al. Restoration of the donor face after facial allotransplantation: digital manufacturing techniques. <em>Annals of Plastic Surgery</em>. 2014:72(6), 720–724. <a href="http://doi.org/10.1097/SAP.0000000000000189">http://doi.org/10.1097/SAP.0000000000000189</a>.</li><li>Huotilainen E, Paloheimo M, Salmi M, et al. Imaging requirements for medical applications of additive manufacturing. <em>Acta Radiologica.</em> 2014:55(1), 78–85. http://doi.org/10.1177/0284185113494198.</li><li>Huotilainen E, Jaanimets R., Valášek J, et al. Inaccuracies in additive manufactured medical skull models caused by the DICOM to STL conversion process <em>Journal of Cranio-Maxillofacial Surgery. </em>2014:42(5), e259–e265. <a href="http://doi.org/10.1016/j.jcms.2013.10.001">http://doi.org/10.1016/j.jcms.2013.10.001</a>.</li><li>Lethaus B, Poort L, Böckmann R, et al. Additive manufacturing for microvascular reconstruction of the mandible in 20 patients. <em>Journal of Cranio-Maxillofacial Surgery</em>. 2012:40(1), 43–46. <a href="http://doi.org/10.1016/j.jcms.2011.01.007">http://doi.org/10.1016/j.jcms.2011.01.007</a>.</li><li>Li Y, Jiang Y, Ye B, et al. Treatment of Dentofacial Deformities Secondary to Osteochondroma of the Mandibular Condyle Using Virtual Surgical Planning and 3-Dimensional Printed Surgical Templates. <em>Journal of Oral Maxillofacial Surgery</em>. 2015:1–20. <a href="http://doi.org/10.1016/j.joms.2015.06.169">http://doi.org/10.1016/j.joms.2015.06.169</a>.</li><li>Mazzoni S, Bianchi A, Schiariti G, et al. Computer-Aided Design and Computer-Aided Manufacturing Cutting Guides and Customized Titanium Plates Are Useful in Upper Maxilla Waferless Repositioning. <em>Journal of Oral Maxillofacial Surgery</em>. 2015:73(4), 701–707. <a href="http://doi.org/10.1016/j.joms.2014.10.028">http://doi.org/10.1016/j.joms.2014.10.028</a>.</li><li>Ogden KM, Aslan C, Ordway N, et al. Factors Affecting Dimensional Accuracy of 3-D Printed Anatomical Structures Derived from CT Data. <em>Journal of Digital Imaging</em>. 2015. <a href="http://doi.org/10.1007/s10278-015-9803-7">http://doi.org/10.1007/s10278-015-9803-7</a>.</li><li>Pinto JM, Arrieta C, Andia ME, et al. Sensitivity analysis of geometric errors in additive manufacturing medical models. <em>Medical Engineering and Physics</em>. 2015:37(3), 328–334. <a href="http://doi.org/10.1016/j.medengphy.2015.01.009">http://doi.org/10.1016/j.medengphy.2015.01.009</a>.</li><li>Ryan JR, Chen T, Nakaji P, et al. Ventriculostomy simulation using patient-specific ventricular anatomy, 3D printing and hydrogel casting. <em>World Neurosurgery</em>. 1–7. <a href="http://doi.org/10.1016/j.wneu.2015.06.016">http://doi.org/10.1016/j.wneu.2015.06.016</a>.</li><li>Wang JQ, Zhao CP, Sun X, et al. Printed three-dimensional anatomic templates for virtual preoperative planning before reconstruction of old pelvic injuries: initial results. <em>Chinese Medical Journal</em>. 2015:128(4), 477–6. <a href="http://doi.org/10.4103/0366-6999.151088">http://doi.org/10.4103/0366-6999.151088</a>.</li><li>Watson RA. A low-cost surgical application of additive fabrication. <em>Journal of Surgical Education</em>. 2014:71(1), 14–17. <a href="http://doi.org/10.1016/j.jsurg.2013.10.012">http://doi.org/10.1016/j.jsurg.2013.10.012</a>.</li><li>Werner H, Santos JRL, Fontes R, et al. Additive manufacturing models of fetuses built from three-dimensional ultrasound, magnetic resonance imaging and computed tomography scan data. <em>Ultrasound in Obstetrics and Gynecology</em>. 2010:36(3), 355–361. http://doi.org/10.1002/uog.7619.</li><li>Wong KC, Kumta SM, Geel NV, et al. One-step reconstruction with a 3D-printed, biomechanically evaluated custom implant after complex pelvic tumor resection. <em>Computer Aided Surgery: Official Journal of the International Society for Computer Aided Surgery</em>. 2015:20(1), 14–23. <a href="http://doi.org/10.3109/10929088.2015.1076039">http://doi.org/10.3109/10929088.2015.1076039</a>.</li><li>Mendez B, Chiodo MV, and Patel PA. Customized “in-office” three-dimensional printing for virtual surgical planning in craniofacial surgery. <em>The Journal of Craniofacial Surgery</em>. 2015:26(5):1584-6. <a href="http://doi.org/10.1097/SCS.0000000000001768">http://doi.org/10.1097/SCS.0000000000001768</a>.</li><li>Peasah SK, McKay NL, Harman JS, et al. Medicare non-payment of hospital-acquired infections: infection rates three years post implementation. <em>Medicaid &amp; Medicare Research Review</em>. 2013:3(3). <a href="https://www.cms.gov/mmrr/Downloads/MMRR2013_003_03_a08.pdf">https://www.cms.gov/mmrr/Downloads/MMRR2013_003_03_a08.pdf</a>.</li><li>Willis DR. How to decide whether to buy new medical equipment. <em>American Academy of Family Physicians</em>. 2004. <a href="http://www.aafp.org/fpm/2004/0300/p53.html">http://www.aafp.org/fpm/2004/0300/p53.html</a>.</li><li>Rybicki F. Medical 3D printing for the radiologist. <em>Radiographics</em>. 2015:35(7):1965-88. <a href="http://www.ncbi.nlm.nih.gov/pubmed/26562233">http://www.ncbi.nlm.nih.gov/pubmed/26562233</a>.</li><li>Small T, Krebs V, Molloy R, et al. Comparison of acetabular shell position using patient specific instruments vs. standard surgical instruments: a randomized clinical trial. <em>The Journal of Arthroplasty</em>. 2014:29(5): 1030–1037. <a href="http://dx.doi.org/10.1016/j.arth.2013.10.006">http://dx.doi.org/10.1016/j.arth.2013.10.006</a>.</li><li>Frakes DH, Ryan JR, Almefty KK, et al. Cerebral aneurysm clipping surgery simulation using patient-specific 3d printing and silicone casting. World Neurosurgery. 2016:88,175-181. <a href="http://www.worldneurosurgery.org/article/S1878-8750(16)00112-1/abstract">http://www.worldneurosurgery.org/article/S1878-8750(16)00112-1/abstract</a>.</li><li>Sher D. New study confirms 3d printing market to grow to $17 billion by 2020. <em>3D Printing Industry</em>. 2015. <a href="http://3dprintingindustry.com/2015/08/24/new-study-confirms-3d-printing-market-grow-17-billion-2020/">http://3dprintingindustry.com/2015/08/24/new-study-confirms-3d-printing-market-grow-17-billion-2020/</a>.</li><li>Zaleski A. Here&#8217;s why 2016 could be 3D printing&#8217;s breakout year. <em>Fortune</em>. 2015. <a href="http://fortune.com/2015/12/30/2016-consumer-3d-printing/">http://fortune.com/2015/12/30/2016-consumer-3d-printing/</a>.</li><li>Sher D. Many 3d printing patents are expiring soon: heres a round up &amp; overview of them. <em>3D Printing Industry</em>. 2015. http://3dprintingindustry.com/2013/12/29/many-3d-printing-patents-expiring-soon-heres-round-overview/.</li><li>Earls A, and Baya V. The road ahead for 3-D printers. <em>PwC</em>. 2014. <a href="http://www.pwc.com/us/en/technology-forecast/2014/3d-printing/features/future-3d-printing.html">http://www.pwc.com/us/en/technology-forecast/2014/3d-printing/features/future-3d-printing.html</a>.</li><li>After explosion, US Department of Labor&#8217;s OSHA cites 3-D printing firm for exposing workers to combustible metal powder, electrical hazards: Powderpart Inc. faces $64,400 in penalties. <em>S. Department of Labor: Occupational Safety &amp; Health Administration.</em> 2014. <a href="https://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=NEWS_RELEASES&amp;p_id=26019">https://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=NEWS_RELEASES&amp;p_id=26019</a>.</li><li>Azimi P, Zhao D, Pouzet C, et al. Emissions of ultrafine particles and volatile organic compounds from commercially available desktop three-dimensional printers with multiple filaments. ACS Publication. 2016. <a href="http://pubs.acs.org/doi/full/10.1021/acs.est.5b04983">http://pubs.acs.org/doi/full/10.1021/acs.est.5b04983</a>.</li><li>3d printing safety. <em>Carnegie Mellon University</em>. <a href="http://www.cmu.edu/ehs/fact-sheets/3D-Printing-Safety.pdf">http://www.cmu.edu/ehs/fact-sheets/3D-Printing-Safety.pdf</a>.</li><li>Columbus L. 2015 roundup of 3d printing market forecasts and estimates. <em>Forbes</em>. 2015. <a href="http://www.forbes.com/sites/louiscolumbus/2015/03/31/2015-roundup-of-3d-printing-market-forecasts-and-estimates/">http://www.forbes.com/sites/louiscolumbus/2015/03/31/2015-roundup-of-3d-printing-market-forecasts-and-estimates/</a>.</li><li>We cant wait: Obama administration announces new public-private partnership to support consortium of businesses, universities, and community colleges from Ohio, West Virginia and Pennsylvania co-invest with federal government in a manufacturing innovation institute. <em>The White House</em>. 2012. <a href="https://www.whitehouse.gov/the-press-office/2012/08/16/we-can-t-wait-obama-administration-announces-new-public-private-partners">https://www.whitehouse.gov/the-press-office/2012/08/16/we-can-t-wait-obama-administration-announces-new-public-private-partners</a>.</li><li>Standard Terminology for Additive Manufacturing – General Principles-Terminology (ASTM) ISO/ASTM 52900:2015(E)</li><li>Gross BC, Erkal JL, Lockwood SY, et al. Evaluation of 3d printing and its potential impact on Biotechnology and the chemical sciences. <em>Analytical Chemistry</em>. 2014:86, 3240-3253. <a href="http://pubs.acs.org/doi/ipdf/10.1021/ac403397r">http://pubs.acs.org/doi/ipdf/10.1021/ac403397r</a>.</li><li>3d printers and 3d printing: technologies, processes and techniques. <em>Sculpteo</em>. <a href="https://www.sculpteo.com/en/3d-printing/3d-printing-technologies/">https://www.sculpteo.com/en/3d-printing/3d-printing-technologies/</a>.</li><li>Davies CT, Baird LM, Jacobson MD, et al. 3d printing of medical devices: when a novel technology meets traditional legal principles. <em>Reed Smith</em>. 2015. <a href="https://www.reedsmith.com/3d-printing-of-medical-devices--when-a-novel-technology-meets-traditional-legal-principles-09-09-2015/">https://www.reedsmith.com/3d-printing-of-medical-devices&#8211;when-a-novel-technology-meets-traditional-legal-principles-09-09-2015/</a>.</li><li>Leinauer M. FDA regulations (or lack thereof) of 3d printed medical devices. <em>Ice Miller Legal Counsel</em>. 2015. http://www.icemiller.com/ice-on-fire-insights/publications/fda-regulations-%28or-lack-thereof%29-of-3d-printed-me/.</li><li>Espalin D, Perez M, Medina F, et al. Sterilization of FDA-manufactured parts. <em>Stratasys</em>. http://web.stratasys.com/rs/objet/images/SSYS-WP-Sterilization-FDM-01-14%20FINAL.pdf.</li><li>CPT process &#8211; how a code becomes a code. <em>American Medical Association</em>. http://www.ama-assn.org/ama/pub/physician-resources/solutions-managing-your-practice/coding-billing-insurance/cpt/cpt-process-faq/code-becomes-cpt.page.</li><li>Gholipour A, Estroff JA, Sahin M, et al. A posteriori estimation of isotropic high-resolution volumetric MRI from orthogonal thick-slice scans. <em>Warfield Departments of Radiology and Neurology, Childrens Hospital Boston, and Harvard Medical School</em>. 2010:13(0 2): 109–116.</li><li>Ejaz F, Ryan J, Henriksen M1, David Frakes, et al. Color-coded patient-specific physical models of congenital heart disease. <em>Rapid Prototyping Journal</em>. 2013. <a href="http://ipalab.fulton.asu.edu/wp-content/JournalPubs/RPJ_2013.pdf">http://ipalab.fulton.asu.edu/wp-content/JournalPubs/RPJ_2013.pdf</a>.</li><li>Matsumoto JS, Morris JM, Foley TA, et al. Three-dimensional physical modeling: applications and experience at Mayo Clinic. <em>RadioGraphics</em>. 2015:35(7), 1989-2006. <a href="http://doi.org/10.1148/rg.2015140260">http://doi.org/10.1148/rg.2015140260</a>.</li><li>Clinical Trials. <a href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</a>.</li><li>Johnson S. Erlanger inks deal with 3D-printer startup to print models of patients&#8217; organs. <em>Times Free Press</em>. 2015. <a href="http://www.timesfreepress.com/news/local/story/2015/oct/12/model-surgery-local-tech-startsays-3-d-mockup/330008/">http://www.timesfreepress.com/news/local/story/2015/oct/12/model-surgery-local-tech-startsays-3-d-mockup/330008/</a>.</li><li>Grunewald SJ. Can 3d digital models be patented? Federal courts to make key decision this summer. <em>com</em>. 2015. <a href="http://3dprint.com/104501/federal-court-3d-model-patent/">http://3dprint.com/104501/federal-court-3d-model-patent/</a>.</li><li>Laser melting (LM). <em>Additively</em>. https://www.additively.com/en/learn-about/laser-melting.</li><li>Layer thickness in 3D printing: an additive manufacturing basic. <em>Sculpteo</em>. <a href="https://www.sculpteo.com/en/glossary/layer-thickness-definition/">https://www.sculpteo.com/en/glossary/layer-thickness-definition/</a>.</li><li>Hospital value-based purchasing. <em>Centers for Medicare &amp; Medicaid Services</em>. 2015: https://www.cms.gov/Medicare/Quality-initiatives-patient-assessment-instruments/hospital-value-based-purchasing/index.html.</li><li><u>M Cotteleer, et al. The 3D Opportunity Primer: the Basics of Additive Manufacturing. Deloitte University Press. March 6, 2014. </u>http://dupress.com/articles/the-3d-opportunity-primer-the-basics-of-additive-manufacturing/?id=2el:3dp:dupmooc:eng:dup:mmddyy:novoed</li><li>Technical Considerations of Additive Manufacture Medical Device: Draft Guidance for Industry and Food and Drug Administration Staff. 2016. <a href="http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM499809.pdf">http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM499809.pdf</a></li></ol>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"></p>



<h2 class="wp-block-heading" id="h-related-articles">Related Articles:</h2>



<p class="wp-block-paragraph"><a href="https://3dheals.com/category/healthcare-3d-printing-guide" target="_blank" rel="noreferrer noopener">3DHEALS Guides (Collective)</a>&nbsp;– This is where we dive deep into subjects that you will find helpful for your projects and career.</p>



<p class="wp-block-paragraph"><a href="https://3dheals.com/category/blog/experts" target="_blank" rel="noreferrer noopener">3DEALS Expert Corner (Collective)</a>&nbsp;– This is where we invite field experts to write their perspectives in a first-person narrative. To write for this column, please email:&nbsp;<a href="mailto:info@3dheals.com" target="_blank" rel="noreferrer noopener">info@3dheals.com</a></p>



<p class="wp-block-paragraph"><a href="https://3dheals.com/category/blog/from-academia" target="_blank" rel="noreferrer noopener">3DHEALS From Academia (Collective)</a>&nbsp;– This section features recent, relevant, close to commercialization academic publications in the space of healthcare 3D printing, 3D bioprinting, and related emerging technologies.</p>
<p>The post <a href="https://3dheals.com/reference/">3D Printing in Hospitals (Guide): Acknowledgement, References</a> appeared first on <a href="https://3dheals.com">3DHeals</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://3dheals.com/reference/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Interview: Paul Gadiock, Overcoming FDA Challenges with 3D Printed Medical Products</title>
		<link>https://3dheals.com/interview-paul-gadiock-overcoming-fda-challenges-with-3d-printed-medical-products/</link>
					<comments>https://3dheals.com/interview-paul-gadiock-overcoming-fda-challenges-with-3d-printed-medical-products/#respond</comments>
		
		<dc:creator><![CDATA[Jenny Chen, M.D.]]></dc:creator>
		<pubDate>Fri, 29 May 2020 19:57:48 +0000</pubDate>
				<category><![CDATA[Blog]]></category>
		<category><![CDATA[Influencer Interviews]]></category>
		<category><![CDATA[3D Printing medical device]]></category>
		<category><![CDATA[FDA]]></category>
		<guid isPermaLink="false">https://3dheals.com/?p=23712</guid>

					<description><![CDATA[<p><a href="https://3dheals.com">3DHeals - Discover 3D Bioprinting and Healthcare Innovations</a></p>
<p>Paul Gadiock is counsel in the San Francisco office of Wilson Sonsini Goodrich &#38; Rosati, where his practice primarily focuses on representing medical device companies, small and large alike, inefficiently navigating local and national regulatory requirements. He brings unique first-hand experience with the development and application of regulatory programs to counsel clients at all stages [&#8230;]</p>
<p>The post <a href="https://3dheals.com/interview-paul-gadiock-overcoming-fda-challenges-with-3d-printed-medical-products/">Interview: Paul Gadiock, Overcoming FDA Challenges with 3D Printed Medical Products</a> appeared first on <a href="https://3dheals.com">3DHeals</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><a href="https://3dheals.com">3DHeals - Discover 3D Bioprinting and Healthcare Innovations</a></p>

<div class="wp-block-image"><figure class="alignleft size-large is-resized"><img loading="lazy" decoding="async" src="https://3dheals.com/wp-content/uploads/2020/05/Gadiock_Paul-2-1.jpg" alt="Paul Gadiock" class="wp-image-23713" width="297" height="365" srcset="https://3dheals.com/wp-content/uploads/2020/05/Gadiock_Paul-2-1.jpg 501w, https://3dheals.com/wp-content/uploads/2020/05/Gadiock_Paul-2-1-447x549.jpg 447w, https://3dheals.com/wp-content/uploads/2020/05/Gadiock_Paul-2-1-244x300.jpg 244w" sizes="auto, (max-width: 297px) 100vw, 297px" /></figure></div>



<p class="wp-block-paragraph"><strong><a href="https://www.linkedin.com/in/paul-gadiock-789231b0/" target="_blank" rel="noreferrer noopener">Paul Gadiock</a></strong> is counsel in the San Francisco office of Wilson Sonsini Goodrich &amp; Rosati, where his practice primarily focuses on representing medical device companies, small and large alike, inefficiently navigating local and national regulatory requirements. He brings unique first-hand experience with the development and application of regulatory programs to counsel clients at all stages of the medical product life cycle. Paul provides premarket and postmarket regulatory solutions for medical product clients. Previously, he served on the senior leadership team at the Center for Devices and Radiological Health of the U.S. Food and Drug Administration (FDA). In this role, he advised key agency officials on issues related to the application of policies, programs, regulations, and legislation and was instrumental in appropriately encompassing or excluding devices from the scope of medical product regulation. Paul also minimized legal risk in Government Accountability Office (GAO) and Office of Inspector General (OIG) investigations, major national programs such as unique device identification (UDI), and medical device cybersecurity, as well as specific matters involving petitions and appeals to the FDA. In addition, he conducted numerous presentations and trained staff on how to streamline complex processes to reduce costs. Before his directorship role at the FDA, Paul served as a business development executive at a national diagnostic biotechnology company, advising international directors on how the company could comply efficiently, leading to cost-effective development of products that could be marketed in multiple countries with different regulatory requirements. Paul united scientists and sales teams to develop an extensive strategy that enhanced the company&#8217;s image and visibility by launching aggressive marketing campaigns. Paul will be speaking on <strong>&#8220;Legal and Regulatory Landscape for Healthcare 3D Printing&#8221;</strong> panel, discussing &#8220;Overcoming FDA Challenges with 3D Printed Medical Products&#8221; <a href="https://www.eventbrite.com/e/global-healthcare-3d-printing-bioprinting-summit-tickets-67890352873" target="_blank" rel="noreferrer noopener">on June 6th, 2020. </a></p>



<p class="wp-block-paragraph"><strong>Jenny</strong>: When was it like when you first encountered the concept of 3D printing?</p>



<p class="wp-block-paragraph"><strong>Paul: </strong>So much intrigue.&nbsp; When I was a kid, I loved taking things apart and putting them back together.&nbsp; I liked seeing where each of the individual components was made and the material.&nbsp; 3D printing turned all that on its head.&nbsp; But I wasn’t disappointed that my childhood experience was phasing out, it just meant a whole new area opened up to be fascinated with.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny</strong>: What inspired you to start your legal practice focusing on 3D printed medical devices?</p>



<p class="wp-block-paragraph"><strong>Paul</strong>: I have a friend from school who knew I was doing a lot of cutting edge FDA work.&nbsp; My friend works at a medium-size 3D printing company with some health applications and tapped me for a project.&nbsp; It had to do with marketing for health applications and gave me an opportunity to get more familiarized with the technology and sensitive issues.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny</strong>: Who inspired you the most along this journey?</p>



<p class="wp-block-paragraph"><strong>Paul</strong>: My clients.&nbsp; Their ideas keep me on my toes and prompt me to think creatively and be resourceful.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny</strong>: What are most passionate about right now?</p>



<p class="wp-block-paragraph"><strong>Paul: </strong>Helping create an advocacy trade association to help shape FDA’s 3D Printing policy.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny</strong>: What do you think what has not been done enough in the regulatory space?</p>



<p class="wp-block-paragraph"><strong>Paul</strong>: There isn’t enough clear policy on FDA’s regulatory policies.&nbsp; Yes, that might mean I get more client work, but it also builds uncertainty.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny</strong>: What are you biggest accomplishments in 2019? And any big plans for 2020?</p>



<p class="wp-block-paragraph"><strong>Paul</strong>: Last year I moved to a new firm and found a great home at <a rel="noreferrer noopener" href="https://www.wsgr.com/en/" target="_blank">WSGR</a>.&nbsp; I was lucky enough to have my clients come with me.&nbsp; This year, my plan is to do even more healthcare work.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny</strong>:  What are some of the most notable progress made in the regulatory field of 3D printing medical devices in 2019? Anything we should hope for in 2020?</p>



<p class="wp-block-paragraph"><strong>Paul: </strong>More bio-printing pioneers.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny</strong>: If you can go back 5 or 10 years, what would you have done differently?</p>



<p class="wp-block-paragraph"><strong>Paul: </strong>I might have left FDA sooner, but the agency was in a tough spot and I didn’t want to abandon my colleagues. &nbsp;</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny</strong>: Software, materials, or 3D printers. It has been a debate in the industry forever as to which is the most important player. What do you think is the most important player in healthcare 3D printing?</p>



<p class="wp-block-paragraph"><strong>Paul</strong>: I think it’s a 3-legged stool.&nbsp; But if I could lean the stool against the wall, I would probably lean off the printer leg.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny</strong>: What motivates you the most for your work?</p>



<p class="wp-block-paragraph"><strong>Paul</strong>: Being the best version of me I can be and making my clients happy.&nbsp; I’m a people pleaser.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny</strong>: What do you think are the biggest challenges in bio-printing? What do you think the potential solutions are?</p>



<p class="wp-block-paragraph"><strong>Paul</strong>:  From a technical standpoint, I understand tissue vascularization is a huge challenge.&nbsp; From a regulatory point of view, there is no established pathway to market.&nbsp; But FDA tends to be reactionary in these circumstances to gain experience so I don’t see a lot of movement on the regulatory side until the technical challenges are ironed out.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny</strong>: What advice would you give to a smart driven college student in the “real world”? What bad advice do you think they should ignore?</p>



<p class="wp-block-paragraph"><strong>Paul</strong>: It’s difficult to say but if I go into that encounter thinking I will be the one to impart wisdom, I’m losing out on an opportunity to learn from the college student.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny</strong>: If you could have a giant billboard to promote a message to millions and even billions of people in the 3DHEALS community, what message would that be?</p>



<p class="wp-block-paragraph"><strong>Paul</strong>: I haven’t worked out a good catch-phrase but in developing industries, it’s important to realize the public judges the industry as a whole.&nbsp; One bad actor can reflect on the whole segment.&nbsp; So it’s important to self-police so that others don’t step in and police you.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny</strong>: What was the biggest risk you took in your career?</p>



<p class="wp-block-paragraph"><strong>Paul</strong>: Leaving FDA and going to private practice was a huge leap for me but I couldn’t be happier with the move.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny</strong>: What do you enjoy in your spare time? What are you passionate about outside of your work/3d printing?</p>



<p class="wp-block-paragraph"><strong>Paul</strong>: I moved from DC to SF about 2 years ago.&nbsp; The climate and scenery here are incredible.&nbsp; I worked a good amount so every opportunity I get, I’m exploring CA.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny</strong>: What is your favorite quote? Why?</p>



<p class="wp-block-paragraph"><strong>Paul</strong>: “Above all, be flexible.”&nbsp; It’s a quote I heard while traveling and when I face challenges, it helps me become poised and take pride in the change I may have originally resisted.&nbsp;</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"><strong>Jenny</strong>: What does the word “3DHEALS” mean to you?&nbsp; =)</p>



<p class="wp-block-paragraph">Paul: It’s an intersection of two areas I’m passionate about – health and technology.&nbsp; So to me, it only means good things (that aren’t easy to conquer).</p>



<p class="wp-block-paragraph"></p>



<h2 class="wp-block-heading">Related Articles: </h2>



<p class="wp-block-paragraph"><a rel="noreferrer noopener" href="https://3dheals.com/interview-with-roger-kuan-intellectual-property-concern-for-healthcare-3d-printing" target="_blank">Interview with Roger Kuan, Intellectual Property Concern for Healthcare 3D Printing</a></p>



<p class="wp-block-paragraph"><a rel="noreferrer noopener" href="https://3dheals.com/patent-protection-medical-3d-printing-bioprinting" target="_blank">Patent Protection for Medical 3D Printing &amp; Bioprinting Technologies</a></p>



<p class="wp-block-paragraph"><a rel="noreferrer noopener" href="https://3dheals.com/protecting-the-ip-in-your-3d-printable-digital-files" target="_blank">Protecting the Intellectual Property (IP) in your 3D Printable Digital Files: A Case Study in the Theft of CAD Files</a></p>



<p class="wp-block-paragraph"><a rel="noreferrer noopener" href="https://3dheals.com/five-reasons-cybersecurity-will-play-a-critical-role-in-3d-printing-in-healthcare-part-3" target="_blank">Five Reasons Cybersecurity Will Play a Critical Role in 3D Printing in Healthcare – Part 3</a></p>



<p class="wp-block-paragraph"><a rel="noreferrer noopener" href="https://3dheals.com/hippa-outsourcing-medical-3d-printing" target="_blank">Legal: Take Care Not to Trigger HIPAA When Outsourcing Medical 3D Printing</a></p>



<p class="wp-block-paragraph"><a rel="noreferrer noopener" href="https://3dheals.com/cybersecurity-for-3d-printed-medical-devices-less-crazy-and-more-useful-than-bitcoins/" target="_blank">Cybersecurity for 3D Printed Medical Devices: Less Crazy and More Useful Than Bitcoins</a></p>



<p class="wp-block-paragraph"><a rel="noreferrer noopener" href="https://3dheals.com/patent-and-fda-market-exclusivity-strategies" target="_blank">3D Bioprinting and Biologics: A Look at Patent and FDA Market Exclusivity Strategies</a></p>



<p class="wp-block-paragraph"><a rel="noreferrer noopener" href="https://3dheals.com/3d-printing-poses-unique-security-risks-medical-devices/" target="_blank">3D Printing Poses Unique Security Risks for Medical Devices</a></p>



<p class="wp-block-paragraph"><a rel="noreferrer noopener" href="https://3dheals.com/from-san-francisco-happening-to-a-legal-limbo" target="_blank">Medtech 3D printing: From a San Francisco happening to a legal limbo</a></p>



<p class="wp-block-paragraph"><a rel="noreferrer noopener" href="https://3dheals.com/3d-printings-legal-landscape-remains-wild-untamed" target="_blank">3D Printing’s Legal Landscape Remains Wild,&nbsp;Untamed</a></p>



<p class="wp-block-paragraph"></p>
<p>The post <a href="https://3dheals.com/interview-paul-gadiock-overcoming-fda-challenges-with-3d-printed-medical-products/">Interview: Paul Gadiock, Overcoming FDA Challenges with 3D Printed Medical Products</a> appeared first on <a href="https://3dheals.com">3DHeals</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://3dheals.com/interview-paul-gadiock-overcoming-fda-challenges-with-3d-printed-medical-products/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Interview: Richard McFarland, Chief Regulatory Officer, ARMI</title>
		<link>https://3dheals.com/interview-richard-mcfarland-armi/</link>
					<comments>https://3dheals.com/interview-richard-mcfarland-armi/#respond</comments>
		
		<dc:creator><![CDATA[Jenny Chen, M.D.]]></dc:creator>
		<pubDate>Sun, 09 Jun 2019 06:29:34 +0000</pubDate>
				<category><![CDATA[Blog]]></category>
		<category><![CDATA[Influencer Interviews]]></category>
		<category><![CDATA[3dprinting]]></category>
		<category><![CDATA[bioprinting]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[regenerative medicine]]></category>
		<guid isPermaLink="false">https://3dheals.com/?p=17339</guid>

					<description><![CDATA[<p><a href="https://3dheals.com">3DHeals - Discover 3D Bioprinting and Healthcare Innovations</a></p>
<p>Richard McFarland, Ph.D., MD joins ARMI as the Chief Regulatory Officer effective May 1, 2017.  Dr. McFarland comes to ARMI from the Food and Drug Administration’s Center for Biologics Evaluation and Research (FDA/CBER) where his career spanning 16 years involved review over an extensive range of products and policy development in numerous areas both inside FDA, across the federal government, and internationally. He spent more than a decade as Associate Director of Policy for FDA/CBER’s Office of Tissues and Advanced Therapies and its predecessor office, the Office of Cellular, Tissue and Gene Therapies. In this position, he was heavily involved in policy development for tissue engineering, regenerative medicine, and alternatives to animal use in regulatory decision making. In addition to the development of risk-based regulatory oversight paradigms within FDA, his interests included broader efforts to create an interlocking network of interagency efforts to foster the growth of basic and translational science to support the maturation of the overlapping fields of tissue engineering and regenerative medicine from primarily discovery science toward a stage of commercial development.</p>
<p>His position at ARMI will allow him to apply the knowledge and experiences gained by over the last decade and half in the field to ARMI’s efforts to establish an industrial common, in the form of a Manufacturing Innovation Institute within the Manufacturing USA network, with the aims to coalesce the field and provide a route for nascent product concepts to reach the marketplace. Bringing these products to the market will benefit critical U.S. public health needs and will provide the economic drivers needed to create new highly-skilled jobs.</p>
<p>Dr. McFarland, Ph.D., M. D. received his B.S., Ph.D., and M.D. from the University of North Carolina at Chapel Hill, and completed his anatomic/clinical pathology residency and immunopathology fellowship training at UT Southwestern in Dallas. Immediately prior to joining the FDA, he was on the faculty of the Pathology Department of the University of Texas Southwestern in Dallas.  In addition to FDA policy documents, he has co-authored over 25 articles in peer-reviewed articles journals including Nature, the Proceedings of the National Academy of Science (PNAS), and Blood. Dr. McFarland will be speaking at our upcoming Boston event this July. </p>
<p>The post <a href="https://3dheals.com/interview-richard-mcfarland-armi/">Interview: Richard McFarland, Chief Regulatory Officer, ARMI</a> appeared first on <a href="https://3dheals.com">3DHeals</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><a href="https://3dheals.com">3DHeals - Discover 3D Bioprinting and Healthcare Innovations</a></p>
<p><img loading="lazy" decoding="async" class="alignleft wp-image-17092 " src="https://3dheals.com/wp-content/uploads/2019/05/Richard-McFarland_Head-Shot-300x300.jpg" alt="" width="240" height="240" srcset="https://3dheals.com/wp-content/uploads/2019/05/Richard-McFarland_Head-Shot-300x300.jpg 300w, https://3dheals.com/wp-content/uploads/2019/05/Richard-McFarland_Head-Shot-245x245.jpg 245w, https://3dheals.com/wp-content/uploads/2019/05/Richard-McFarland_Head-Shot-100x100.jpg 100w, https://3dheals.com/wp-content/uploads/2019/05/Richard-McFarland_Head-Shot-150x150.jpg 150w, https://3dheals.com/wp-content/uploads/2019/05/Richard-McFarland_Head-Shot-250x250.jpg 250w, https://3dheals.com/wp-content/uploads/2019/05/Richard-McFarland_Head-Shot.jpg 317w" sizes="auto, (max-width: 240px) 100vw, 240px" /><strong>Richard McFarland, Ph.D., MD</strong> joins <a href="http://www.armiusa.org/">ARMI</a> as the Chief Regulatory Officer effective May 1, 2017.&nbsp; Dr. McFarland comes to ARMI from the Food and Drug Administration’s Center for Biologics Evaluation and Research (FDA/CBER) where his career spanning 16 years involved review over an extensive range of products and policy development in numerous areas both inside FDA, across the federal government, and internationally. He spent more than a decade as Associate Director of Policy for FDA/CBER’s Office of Tissues and Advanced Therapies and its predecessor office, the Office of Cellular, Tissue and Gene Therapies. In this position, he was heavily involved in policy development for tissue engineering, regenerative medicine, and alternatives to animal use in regulatory decision making. In addition to the development of risk-based regulatory oversight paradigms within FDA, his interests included broader efforts to create an interlocking network of interagency efforts to foster the growth of basic and translational science to support the maturation of the overlapping fields of tissue engineering and regenerative medicine from primarily discovery science toward a stage of commercial development.</p>
<p>His position at ARMI will allow him to apply the knowledge and experiences gained by over the last decade and half in the field to ARMI’s efforts to establish an industrial common, in the form of a Manufacturing Innovation Institute within the&nbsp;<a href="https://www.manufacturingusa.com/">Manufacturing USA</a>&nbsp;network, with the aims to coalesce the field and provide a route for nascent product concepts to reach the marketplace. Bringing these products to the market will benefit critical U.S. public health needs and will provide the economic drivers needed to create new highly-skilled jobs.</p>
<p>Dr. McFarland, Ph.D., M. D. received his B.S., Ph.D., and M.D. from the University of North Carolina at Chapel Hill, and completed his anatomic/clinical pathology residency and immunopathology fellowship training at UT Southwestern in Dallas. Immediately prior to joining the FDA, he was on the faculty of the Pathology Department of the University of Texas Southwestern in Dallas.&nbsp; In addition to FDA policy documents, he has co-authored over 25 articles in peer-reviewed articles journals including Nature, the Proceedings of the National Academy of Science (PNAS), and Blood. Dr.&nbsp;McFarland will be speaking at our upcoming <a href="https://3dheals.com/boston-annual-summer-event">Boston event</a> this July.&nbsp;</p>
<p></p>


<p class="wp-block-paragraph"><strong>Jenny: When was the first encounter you had with 3D printing?  </strong></p>



<p class="wp-block-paragraph"><span style="color: #cc145f;"><strong>Richard:</strong></span> It was probably about 10 years ago, while I was at <a href="https://www.fda.gov/home" target="_blank" rel="noreferrer noopener" aria-label="FDA (opens in a new tab)">FDA</a> when I had my first experience with 3D printing and I began thinking about the ways that it might fit within the regulatory landscape.</p>



<p class="wp-block-paragraph"><strong>Jenny: What inspired you to start your journey research in 3D printing/bio-fabrication?</strong></p>



<p class="wp-block-paragraph"><span style="color: #cc145f;"><strong>Richard:</strong></span> It was my desire to ensure that all scientifically reasonable technologies could develop within a regulatory landscape in a way that would allow adequate safeguards for the safety of research participants and eventually patients once products were commercialized.</p>



<p class="wp-block-paragraph"><strong>Jenny: Who inspired you the most along this journey in bioprinting and regenerative medicine? </strong></p>



<p class="wp-block-paragraph"><span style="color: #cc145f;"><strong>Richard:</strong></span> There were very numerous, and as a result I am hesitant to name specific people, however I would like to specifiy three groups of people as inspirations.</p>



<p class="wp-block-paragraph">First, patients with life-threatening and life-altering diseases and syndromes for which the currently available therapies fall significantly short. Those patients who must endure multiple surgeries due to the fact that current conventional medical devices cannot offer curative treatments and/or multiple surgeries with inadequate repairs fashioned from autologous tissues that also subject them to iatrogenic donor site morbidities. Patients (and parents if the patients are children) must face heart-wrenching decisions among a series of inadequate options. There is potential with bio-printing bio-fabrication to provide better clinical solutions, which may be in some cases curative if research findings can be successfully translated into medical products.</p>



<p class="wp-block-paragraph">Second, I would have to say that I have been inspired by the efforts of many of the public servants across the federal government (and other governments around the world) with whom I have had the privilege to work with over my years at FDA. These individuals wrestle with difficult decisions of balancing innovation and clinical trial participant/patient safety across constantly changing fields each day, year in an year out, with full recognition essentially in anonymity without any expectation of extreme fortune or fame because, in most cases, they recognize that they are making a contribution in some way to the general wellbeing and public health. This is true of the public servants that I have worked with across the entire government, not just at my home agency- FDA, but at <a rel="noreferrer noopener" aria-label="NIH (opens in a new tab)" href="https://www.nih.gov/" target="_blank">NIH</a>, <a rel="noreferrer noopener" aria-label="NSF (opens in a new tab)" href="https://www.nsf.gov/" target="_blank">NSF</a>, <a rel="noreferrer noopener" aria-label="NIST (opens in a new tab)" href="https://www.nist.gov/" target="_blank">NIST</a>, and <a href="https://www.defense.gov/" target="_blank" rel="noreferrer noopener" aria-label="DoD (opens in a new tab)">DoD</a>.</p>



<p class="wp-block-paragraph">Last and most recently, I have been inspired by my colleagues at <a rel="noreferrer noopener" aria-label="ARMI|BIoFabUSA (opens in a new tab)" href="https://www.armiusa.org/" target="_blank">ARMI|BIoFabUSA</a> as I have discovered the diverse, and at times very personally touching, reasons that they have chosen to contribute their talents and efforts to the Institute’s efforts to manufacture the future of biofabrication which, will in time, make good on the promises offered by biomedical research.</p>



<p class="wp-block-paragraph"><strong>Jenny: What is/are the biggest obstacle(s) in your line of work? If you have conquered them, what were your solutions?</strong></p>



<p class="wp-block-paragraph"><span style="color: #cc145f;"><strong>Richard:</strong></span> The largest obstacles in the cross-disciplinary role that I currently fill is maintaining sufficient knowledge across many adjacent files of science, engineering, medicine, manufacuticuring, business, law, politics to anticipate what needs to be aligned in sufficient time to ensure that the resources and other ingredients needed for moving the field forward are available when it is the appropriate time to make a difference.</p>



<p class="wp-block-paragraph"><strong>Jenny: What do you think is (are) the biggest challenge(s) in bio-printing? What do you think the potential solution(s) is (are)?</strong></p>



<p class="wp-block-paragraph"><span style="color: #cc145f;"><strong>Richard:</strong></span> The biggest challenge in bioprinting in terms of it being used to produce a therapeutic product is having a product developed to a sufficient stage to go into clinical trials and gain a marketing authorization. When this happens, it will demonstrate that there is a pathway to commercialization of this technology in the therapeutic realm. There are numerous technical and regulatory hurdles to address that challenge, but they are somewhat unique to the product and application, however, if the underlying scientific research is stable they are all achievable.</p>



<p class="wp-block-paragraph"><strong>Jenny: What were/was the best and worst investment you made in bio-printing/bio-fabrication? </strong></p>



<p class="wp-block-paragraph"><span style="color: #cc145f;"><strong>Richard:</strong></span> Too early to tell.</p>



<p class="wp-block-paragraph"><strong>Jenny: What was/is the biggest risk you took in your career?</strong></p>



<p class="wp-block-paragraph"><span style="color: #cc145f;"><strong>Richard:</strong></span> Probably leaving academia, and the relatively sure future of a clinician/scientist to come to work in the FDA because it had the potential (and did) change the course of my career and life.</p>



<h2 class="wp-block-heading">Related Articles: </h2>



<p class="wp-block-paragraph"><strong><a rel="noreferrer noopener" aria-label="Interview: Gray Chynoweth, Chief Membership Officer for ARMI | BioFabUSA (opens in a new tab)" href="https://3dheals.com/3dheals-influencer-interview-gray-chynoweth" target="_blank">Interview: Gray Chynoweth, Chief Membership Officer for ARMI | BioFabUSA</a></strong></p>



<p class="wp-block-paragraph"><strong><a rel="noreferrer noopener" aria-label="Community Manager Interview: Gerald Matarazzo, Boston (opens in a new tab)" href="https://3dheals.com/community-manager-interview-gerald-matarazzo-boston" target="_blank">Community Manager Interview: Gerald Matarazzo, Boston</a></strong></p>



<p class="wp-block-paragraph"><strong><a href="https://3dheals.com/3d-bioprinting-truth-beautiful" target="_blank" rel="noreferrer noopener" aria-label="3D Bioprinting: Truth is Beautiful— How Close are We to Artificial Tissues and&nbsp;Organs?
 (opens in a new tab)">3D Bioprinting: Truth is Beautiful— How Close are We to Artificial Tissues and&nbsp;Organs?<br></a></strong><br></p>
<p>The post <a href="https://3dheals.com/interview-richard-mcfarland-armi/">Interview: Richard McFarland, Chief Regulatory Officer, ARMI</a> appeared first on <a href="https://3dheals.com">3DHeals</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://3dheals.com/interview-richard-mcfarland-armi/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>3D Bioprinting and Biologics: A Look at Patent and FDA Market Exclusivity Strategies</title>
		<link>https://3dheals.com/patent-and-fda-market-exclusivity-strategies/</link>
					<comments>https://3dheals.com/patent-and-fda-market-exclusivity-strategies/#respond</comments>
		
		<dc:creator><![CDATA[Jeff Vockrodt]]></dc:creator>
		<pubDate>Sat, 02 Feb 2019 18:08:58 +0000</pubDate>
				<category><![CDATA[Blog]]></category>
		<category><![CDATA[Expert's Corner]]></category>
		<category><![CDATA[bioprinting]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[legal]]></category>
		<category><![CDATA[patent]]></category>
		<category><![CDATA[tissue engineering]]></category>
		<guid isPermaLink="false">https://3dheals.com/?p=12407</guid>

					<description><![CDATA[<p><a href="https://3dheals.com">3DHeals - Discover 3D Bioprinting and Healthcare Innovations</a></p>
<p>The industrialization of 3D printing opens the possibility of making products efficiently with complex structure previously thought impossible or impractical using the tools of the first industrial revolution. Early industrial applications of 3D printed metal parts lowered the weight and reduced the number of components for highly engineered components, such as jet aircraft engine parts. As innovators seek to increase applications, much effort has been underway to expand available materials to include biopolymers and even tissue or cells. </p>
<p>3D bioprinting employs 3D printing and similar techniques to combine cells, growth factors, and biocompatible materials to fabricate products that mimic natural materials such as printed bone, skin, arteries, and even whole organs. The promise of 3D bioprinting is to leverage the computer-controlled, layer-by-layer additive process of 3D printing to selectively deposit cells to build complex living tissues that can be used in patients. Because the cells can come from the patient, there would be no need for organ donors, and lessened risk of transplant rejection.    </p>
<p>Bringing these 3D bioprinted products to market will require significant investment in order to gain marketing approval from the Food &#038; Drug Administration (FDA). The question immediately arises as to whether innovators in 3D bioprinting will be able to leverage enough patent and FDA marketing exclusivity to make their investment worthwhile. Both (1) the type of patents available and (2) the regulatory pathway chosen will determine the amount of exclusivity available for first movers.</p>
<p>The post <a href="https://3dheals.com/patent-and-fda-market-exclusivity-strategies/">3D Bioprinting and Biologics: A Look at Patent and FDA Market Exclusivity Strategies</a> appeared first on <a href="https://3dheals.com">3DHeals</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><a href="https://3dheals.com">3DHeals - Discover 3D Bioprinting and Healthcare Innovations</a></p>
<p>Co-Authored by:&nbsp;<a href="https://3dheals.com/3dheals-influencer-interview-jeff-vockrodt/"><strong>Jeff Vockrodt</strong>&nbsp;</a>&nbsp;and&nbsp;<strong>Paul&nbsp;Gadiock</strong>&nbsp;</p>
<p><strong><em>Want to write a piece for </em></strong><a href="https://3dheals.com/category/blog/experts"><strong><em>3DHEALS Expert Corner</em></strong></a><strong><em>? Email us: info@3dheals.com</em></strong></p>
<p>The industrialization of 3D printing opens the possibility of making products efficiently with complex structure previously thought impossible or impractical using the tools of the first industrial revolution. Early industrial applications of 3D printed metal parts lowered the weight and reduced the number of components for highly engineered components, such as jet aircraft engine parts. As innovators seek to increase applications, much effort has been underway to expand available materials to include biopolymers and even tissue or cells.<span class="Apple-converted-space">&nbsp;</span></p>
<p><img loading="lazy" decoding="async" class="wp-image-12408 size-medium alignleft" src="https://3dheals.com/wp-content/uploads/2019/01/drew-hays-206414-unsplash-min-200x300.jpg" alt="" width="200" height="300" srcset="https://3dheals.com/wp-content/uploads/2019/01/drew-hays-206414-unsplash-min-200x300.jpg 200w, https://3dheals.com/wp-content/uploads/2019/01/drew-hays-206414-unsplash-min-447x671.jpg 447w, https://3dheals.com/wp-content/uploads/2019/01/drew-hays-206414-unsplash-min.jpg 600w" sizes="auto, (max-width: 200px) 100vw, 200px" /></p>
<p>3D bioprinting employs 3D printing and similar techniques to combine cells, growth factors, and biocompatible materials to fabricate products that mimic natural materials such as printed bone, skin, arteries, and even whole organs. The promise of 3D bioprinting is to leverage the computer-controlled, layer-by-layer additive process of 3D printing to selectively deposit cells to build complex living tissues that can be used in patients. Because the cells can come from the patient, there would be no need for organ donors, and lessened risk of transplant rejection. <span class="Apple-converted-space">&nbsp; &nbsp;</span></p>
<p>Bringing these 3D bioprinted products to market will require significant investment in order to gain marketing approval from the Food &amp; Drug Administration (FDA). The question immediately arises as to whether innovators in 3D bioprinting will be able to leverage enough patent and FDA marketing exclusivity to make their investment worthwhile. Both (1) the type of patents available and (2) the regulatory pathway chosen will determine the amount of exclusivity available for first movers.<span class="Apple-converted-space">&nbsp;</span></p>
<h3>Patents for 3D Bioprinting</h3>
<p>Patents generally provide their owner with a right to exclude others for a limited time period from making, using, offering to sell, or selling the patented invention.<span class="Apple-converted-space">&nbsp;</span></p>
<p>The scope of what the patent covers is determined by (1) the category of the patent claim being made (e.g., product, the method of using, or method of making), and (2) the breadth of the claim language. To obtain a patent an invention must be new, non-obvious, and directed to the patent-eligible subject matter.<span class="Apple-converted-space">&nbsp;</span></p>
<p>Printing organs will require new printing techniques and materials. The initial patents found in 3D bioprinting will likely focus on these technologies. One of the main challenges for these kinds of pioneering patents is that they will likely be at or near expiry by the time 3D bioprinted products become available. This happened with other 3D printing technologies and commonly occurs with pioneering patents particularly where a patent term of 20 years is linked to the filing date. A repeat of the early 3D printing patent wars is less likely in the bioprinting space where the <a href="https://www.jdsupra.com/legalnews/safe-harbor-provision-of-35-u-s-c-271-e-75236/">safe harbor provisions of 35 U.S.C. 271(e)</a> may shield those practicing the technologies in order to gain FDA approval of 3D bioprinted products.</p>
<p>As the time for regulatory submission and approval approach, 3D bioprinters will likely file more patents directed to the products for which approval is sought. In general, product claims offer the patent owner a broader scope of protection relative to method claims. This is because a product claim can only be avoided by changing the product itself, whereas method claims can often be avoided by using the product differently or making it differently. The complexity of 3D bioprinted products will likely provide many avenues for patenting.<span class="Apple-converted-space">&nbsp;</span></p>
<p>The patent portfolios of companies who bring these products to market will likely be large, similar to those found for currently approved biologic products. For example, Abbvie has amassed over 100 patents covering its Humira product. The portfolios would likely include claims to the 3D bioprinted products themselves. These product claims would need to include features that distinguish the claimed subject matter from the prior art, which may present a challenge. Another hurdle for product claims is that they are often filed at an earlier stage of technological development, and may expire before products make it to market. <span class="Apple-converted-space">&nbsp;</span></p>
<p>Aside from patent claims to the products, 3D bioprinting patents will likely also be granted on intermediate products, processes of making (harvesting cells, using cells in bioprinting, constructing organs and tissue from the cells), growth factors and other products used in the manufacturing process. Because 3D printing and bioprinting fundamentally relate to new methods of making, patents directed to various aspects of the process itself may be the most straight forward to obtain. These patents related to the process of 3D bioprinting will likely make up the bulk of patent portfolios covering 3D bioprinted products. <span class="Apple-converted-space">&nbsp;</span></p>
<h3>Regulatory Pathway and Exclusivity for 3D Bioprinting</h3>
<p>The FDA has already acknowledged that bioprinting is on the horizon and that a policy framework is needed to help ensure regulatory consistency and predictability. There are generally three categories of medical products that are regulated by FDA―devices, drugs, and biologics―each with their own range of pathways to market. How a medical product is categorized will dictate the group within the FDA that governs the bioprinted product under its authority:<span class="Apple-converted-space">&nbsp;</span></p>
<p></p>
<table cellspacing="0" cellpadding="0">
<tbody>
<tr>
<td valign="top"><b>Pathway</b></td>
<td valign="top"><b>Responsibility within the FDA</b></td>
</tr>
<tr>
<td valign="top">Medical Device</td>
<td valign="top">Center for Devices and Radiological Health</td>
</tr>
<tr>
<td valign="top">Drug</td>
<td valign="top">Center for Drug Evaluation &amp; Research</td>
</tr>
<tr>
<td valign="top">Biologic</td>
<td valign="top">Center for Biologics Evaluation &amp; Research</td>
</tr>
</tbody>
</table>
<p>Further, bioprinted medical products that share a device, drug, and biologic attributes, so-called “combination products,” can blur the lines between FDA regulatory categories. In these scenarios, the FDA’s Office of Combination Products determines the product’s “primary mode of action” and, in turn, the FDA Center that will have primary jurisdiction over the bioprinted medical product. The determination of the primary mode of action typically has a significant impact because each category of medical products is afforded its own regulatory paradigm, some of which are far more demanding than others.<span class="Apple-converted-space">&nbsp;</span></p>
<p>There has been some debate about whether a 3D bioprinted product would be a medical device, a drug, or a biologic product. Because a 3D bioprinted organ would be implanted into a patient during use, it has led some to believe that it could be regulated as a medical device, similar to a pacemaker. In fact, the FDA has been promoting the development of an artificial pancreas device system; however, the agency has been keen to point out it does not consider products that involve biomaterial, synthetic or artificial tissue or organs to meet this definition. Seeing as how the definition of a medical device requires that it “does not achieve its primary intended purpose through chemical action within or on the body of a man . . . .,” some have argued a device classification for bioprinted products as being unlikely.<span class="Apple-converted-space">&nbsp;</span></p>
<p>More likely, 3D bioprinted products will be deemed either drugs or biologics and regulated as such. FDA regulations define the term “drug,” in part, by reference to its intended use, as “articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease” and “articles (other than food) intended to affect the structure or any function of the body of man or other animals.” Notably, the definition of a drug is very similar to the definition of a device, less the qualifier that it does not achieve its primary intended purpose through chemical action within or on the body.<span class="Apple-converted-space">&nbsp;</span></p>
<p>By implication, drugs can be expected to achieve their primary intended purpose through chemical action. The FDA interprets that a product exhibits “chemical action” if it interacts at the molecular level with bodily components (e.g., cells or tissues) to mediate (including promoting or inhibiting) a bodily response. Under this interpretation, it is apparent that FDA can expect drugs to operate at a molecular level. Contrast that characteristic with cells and tissues that are regulated by FDA as biologics.</p>
<p>Human cells or tissues intended for implantation, transplantation, infusion, or transfer into a human recipient are regulated by FDA as biologics. Examples of these types of products include bone, skin, corneas, ligaments, tendons, dura mater, heart valves. Based on the definition and examples, it is evident that these products are on a different physical scale than the drugs previously described. However, though finished bioprinted products would seem more akin to tissues, the scale on which the product is actually bioprinted may ultimately decide the category in which the medical product will fall. Suffice it to say that FDA’s current regulatory paradigm does not specifically contemplate bioprinted medical products. Legislation may be required to resolve whether the technology would be a drug or biologic, and the consequent patent implications that flow from that decision.</p>
<h3>The Intersection of Regulatory and Patents for 3D Bioprinting</h3>
<p>The <a href="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm613498.htm">Hatch-Waxman Act</a> governs the process for FDA approval of generics for products regulated as drugs. One aspect of Hatch-Waxman is that it links FDA approval of a generic to product and method of therapeutic use patents, which are listed in the <a href="https://www.fda.gov/Drugs/InformationOnDrugs/ucm129662.htm">orange book</a> for each approved product. The existence of orange book patents for a new chemical entity drug can nearly guarantee an additional 2.5 years of market exclusivity on top of the 5 years granted for a new chemical entity, for 7.5 years total. That period may be further extended based on a patent term extension for up to an additional five years for one of the orange book patents.<span class="Apple-converted-space">&nbsp;</span></p>
<p>Hatch-Waxman’s patent linkage leads to a clear preference for product and method of therapeutic use patent for drugs. This allows the patent owner of a drug product bring an infringement lawsuit while lessening the prospect that the generic competitor would launch its generic product “at risk,” meaning while the patent dispute has not been resolved. Because the bulk of a patent portfolio for 3D bioprinting will likely relate to aspects of the bioprinting process itself as discussed above, many of those patents would not be in the orange book. This could make regulation of 3D bioprinted products as drugs less desirable from a patent owner’s perspective. <span class="Apple-converted-space">&nbsp;</span></p>
<p>No such patent linkage exists for biologics and biosimilars, which are regulated under the Biologics Price Competition and Innovation Act (BPCIA) enacted in 2010. Instead of tying the exclusivity to particular patents and extending marketing exclusivity based on the listed patent, approved biologics receive 12 years of market exclusivity regardless of the patent situation. There is no equivalent of the orange book for biologics. Instead, patent owners and biosimilar applicants can engage in a “patent dance” to narrow down the number of patents involved in pre-launch litigation. Unlike Hatch-Waxman litigation for drugs which are limited to product and therapeutic use patents, biosimilars litigation under the BPCIA often involves all kinds of patents, including a method of making patents. This could make the biosimilar regulatory pathway more desirable than the drug pathway for 3D bioprinting patent owners.<span class="Apple-converted-space">&nbsp;</span></p>
<p>While there is some uncertainty as to how the FDA will regulate 3D bioprinting, the<span class="Apple-converted-space">&nbsp;</span>character of these products suggests that assuming no new category of regulation is created, they are likely to be regulated as biologics. The lessons learned from BPCIA litigation is likely relevant for 3D bioprinting. While BPCIA litigation is relatively new, we know that obtaining a large patent portfolio surrounding important products has been important for branded biologics manufacturers. This suggests 3D bioprinters should actively seek to patent all aspects of their 3D bioprinting processes.<span class="Apple-converted-space">&nbsp;</span></p>
<h4>&nbsp;</h4>
<h4>About the Authors:</h4>
<p><img loading="lazy" decoding="async" class="alignleft wp-image-12411 size-medium" src="https://3dheals.com/wp-content/uploads/2019/01/Vockrodt-Jeff-1160x1280-min-272x300.jpg" alt="" width="272" height="300" srcset="https://3dheals.com/wp-content/uploads/2019/01/Vockrodt-Jeff-1160x1280-min-272x300.jpg 272w, https://3dheals.com/wp-content/uploads/2019/01/Vockrodt-Jeff-1160x1280-min-447x493.jpg 447w, https://3dheals.com/wp-content/uploads/2019/01/Vockrodt-Jeff-1160x1280-min-768x847.jpg 768w, https://3dheals.com/wp-content/uploads/2019/01/Vockrodt-Jeff-1160x1280-min-928x1024.jpg 928w, https://3dheals.com/wp-content/uploads/2019/01/Vockrodt-Jeff-1160x1280-min.jpg 837w" sizes="auto, (max-width: 272px) 100vw, 272px" /></p>
<p></p>
<p></p>
<p></p>
<p></p>
<p><a href="https://3dheals.com/3dheals-influencer-interview-jeff-vockrodt/"><strong>Jeff Vockrodt</strong> </a>advises companies on patent matters involving chemical and life science technologies, including pharmaceutical, medical device, and biotechnology inventions. Jeff has overseen the preparation and prosecution of hundreds of patent applications involving a wide range of technologies, including additive manufacturing and biopharmaceutical patents. Jeff has served as lead counsel in inter partes review (IPR) proceedings before the Patent Trial and Appeal Board (PTAB). Jeff is a registered patent attorney with a chemical engineering background. He served for four years as patent examiner before the United States Patent and Trademark Office and a law clerk in the US International Trade Commission before entering private practice. He is currently a partner at Arent Fox LLP and adjunct professor teaching IP, Regulation &amp; Compliance for Biotechnology at Katz Business School, Yeshiva University. <span class="Apple-converted-space">&nbsp;</span></p>
<p></p>
<p><img loading="lazy" decoding="async" class="alignleft size-medium wp-image-12409" src="https://3dheals.com/wp-content/uploads/2019/01/Gadiock-Paul-1160x1280-min-272x300.jpg" alt="" width="272" height="300" srcset="https://3dheals.com/wp-content/uploads/2019/01/Gadiock-Paul-1160x1280-min-272x300.jpg 272w, https://3dheals.com/wp-content/uploads/2019/01/Gadiock-Paul-1160x1280-min-447x493.jpg 447w, https://3dheals.com/wp-content/uploads/2019/01/Gadiock-Paul-1160x1280-min-768x847.jpg 768w, https://3dheals.com/wp-content/uploads/2019/01/Gadiock-Paul-1160x1280-min-928x1024.jpg 928w, https://3dheals.com/wp-content/uploads/2019/01/Gadiock-Paul-1160x1280-min.jpg 837w" sizes="auto, (max-width: 272px) 100vw, 272px" /></p>
<p></p>
<p></p>
<p></p>
<p></p>
<p><strong>Paul&nbsp;Gadiock</strong> is a is a Senior Attorney in Arent Fox’s Life Sciences group where he provides premarket and postmarket regulatory solutions on a variety of subject matters for medical product clients. Paul regularly counsels on conventional medical products as well as transformative technologies including digital health, 3D printed products, and regenerative therapies. As a former policy director at FDA and business development leader at a national biotechnology company, he brings unique first-hand experience with the development and application of regulatory programs to benefit clients at all stages of the medical product life cycle. Paul speaks frequently at industry conferences and writes articles and legal alerts on cutting-edge topics concerning the life sciences sector.<span class="Apple-converted-space">&nbsp;</span></p>
<p></p>


<p class="wp-block-paragraph"><strong>You may also like: </strong></p>



<p class="wp-block-paragraph"><strong><a rel="noreferrer noopener" aria-label="A World of Regulation: Updates on 3D printed Medical Devices (opens in a new tab)" href="https://3dheals.com/updates-on-3d-printed-medical-devices/" target="_blank">A World of Regulation: Updates on 3D printed Medical Devices</a></strong></p>



<p class="wp-block-paragraph"><strong><a rel="noreferrer noopener" label="Interview: Jeff Vockrodt, Partner at Arent Fox (opens in a new tab)" href="https://3dheals.com/interview-jeff-vockrodt-arent-fox/" target="_blank">Interview: Jeff Vockrodt, Partner at Arent Fox</a></strong></p>



<p class="wp-block-paragraph"><strong><a href="https://3dheals.com/metal-3d-printing-in-dentistry-restoration-additive-manufacturing/" target="_blank" rel="noreferrer noopener" aria-label="Metal 3D Printing in Dentistry – Restoration (opens in a new tab)">Metal 3D Printing in Dentistry – Restoration</a></strong></p>
<p>The post <a href="https://3dheals.com/patent-and-fda-market-exclusivity-strategies/">3D Bioprinting and Biologics: A Look at Patent and FDA Market Exclusivity Strategies</a> appeared first on <a href="https://3dheals.com">3DHeals</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://3dheals.com/patent-and-fda-market-exclusivity-strategies/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Decentralized Healthcare — Part II: Breaking It All Down</title>
		<link>https://3dheals.com/decentralized-healthcare-part-2-breaking-it-all-down/</link>
					<comments>https://3dheals.com/decentralized-healthcare-part-2-breaking-it-all-down/#respond</comments>
		
		<dc:creator><![CDATA[Jenny Chen, M.D.]]></dc:creator>
		<pubDate>Mon, 28 Jan 2019 02:47:09 +0000</pubDate>
				<category><![CDATA[Blog]]></category>
		<category><![CDATA[Two Cents]]></category>
		<category><![CDATA[3D-printing]]></category>
		<category><![CDATA[additive manufacture]]></category>
		<category><![CDATA[decentralization]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[healthcare]]></category>
		<category><![CDATA[innovation]]></category>
		<guid isPermaLink="false">https://3dheals.com/?p=12593</guid>

					<description><![CDATA[<p><a href="https://3dheals.com">3DHeals - Discover 3D Bioprinting and Healthcare Innovations</a></p>
<p>To be able to imagine the dramatic change in a system that has existed for thousands of years, stepping away to see the bigger picture is necessary. One important but the overlooked word, “healthcare”, needs to be clearly defined first. Based on Wikipedia (i.e. crowdsourced definition), healthcare is the “maintenance or improvement of health via the prevention, diagnosis, and treatment of disease, illness, injury, and other physical and mental impairment in human beings.” As mentioned in “Decentralized Healthcare Part I”, the current healthcare delivery system is rather centralized. Therefore, an effective decentralized healthcare delivery system needs to serve all the existing roles, if not better, than the current centralized system.</p>
<p>In addition, it is necessary to discuss the concept of “decentralization” within the proper context. As suggested by in one article on bitcoin/computing [ref], there are several rather independent kinds of decentralization. In healthcare, perhaps we can break it down to the following three:</p>
<p>The post <a href="https://3dheals.com/decentralized-healthcare-part-2-breaking-it-all-down/">Decentralized Healthcare — Part II: Breaking It All Down</a> appeared first on <a href="https://3dheals.com">3DHeals</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><a href="https://3dheals.com">3DHeals - Discover 3D Bioprinting and Healthcare Innovations</a></p>
<p>To be able to imagine the dramatic change in a system that has existed for thousands of years, stepping away to see the bigger picture is necessary. One important but the overlooked word, “healthcare”, needs to be clearly defined first. Based on <a href="https://en.m.wikipedia.org/wiki/Health_care" data-href="https://en.m.wikipedia.org/wiki/Health_care">Wikipedia</a> (i.e. crowdsourced definition), healthcare is the “maintenance or improvement of health via the prevention, diagnosis, and treatment of disease, illness, injury, and other physical and mental impairment in human beings.” As mentioned in “<a href="https://3dheals.com/decentralized-healthcare%e2%80%8a-%e2%80%8apart-i-cooler-than-bitcoins-but-what-is-it/" data-href="https://3dheals.com/decentralized-healthcare%e2%80%8a-%e2%80%8apart-i-cooler-than-bitcoins-but-what-is-it/">Decentralized Healthcare Part I</a>”, the current healthcare delivery system is rather centralized. Therefore, an effective decentralized healthcare delivery system needs to serve all the existing roles, if not better, than the current centralized system.</p>
<p>In addition, it is necessary to discuss the concept of “decentralization” within the proper context. As suggested by in one article on bitcoin/computing [<a href="https://medium.com/@VitalikButerin/the-meaning-of-decentralization-a0c92b76a274" data-href="https://medium.com/@VitalikButerin/the-meaning-of-decentralization-a0c92b76a274">ref</a>], there are several rather independent kinds of decentralization. In healthcare, perhaps we can break it down to the following three:</p>
<p>&nbsp;</p>
<p><strong>1. Physical Decentralization</strong> — A healthcare delivery system that is less dependent on physical location or number of the human healthcare provider. Achievements of the prevention, diagnosis, and treatment of disease would require less and less physical conglomerate of technologies and human providers. As Vinod Khosla suggested in his paper, <a href="https://www.khoslaventures.com/20-percent-doctor-included-speculations-and-musings-of-a-technology-optimist" data-href="https://www.khoslaventures.com/20-percent-doctor-included-speculations-and-musings-of-a-technology-optimist">“’20 Percent Doctor Included’ &amp; Dr. Algorithm: Speculations and Musings of a Technology Optimist “,</a> Dr. Algorithm will likely take over “80%” of what doctors do today. The role of future doctors will dramatically change with the rising of technology and the ceiling of the healthcare budget. The role of hospitals and healthcare organizations will also have to change, and more likely towards physical decentralization. There are many existing innovations targeting physical decentralization of healthcare already:</p>
<p>&nbsp;</p>
<p><strong>&nbsp; &nbsp; &nbsp;a.Prevention</strong>: Our progressively improved ability to easily (and cheaply) obtain and store data either from IoT and wearables or remote diagnostic labs and devices allow us to collect not only a lot more data but often continuous data from patients. This reduces the need for the patient to physically visit their doctors, clinics, hospitals for checkups and follow-ups.</p>
<p>&nbsp;</p>
<p><strong>&nbsp; &nbsp; b.Diagnosis</strong>: Remote monitoring, remote diagnosis, telemedicine/teledentistry are more and more common and accepted. Patients are more open to cheaper, more accessible, but perhaps less intimate interaction with the new care delivery interface, ranging from robots to an iPhone with a human on the other end of the screen. What often started out as the target of skeptics is then accepted as a form of reimbursable procedure accepted by most major insurance companies. In the world of diagnostic imaging, handheld 3D scanner and <a href="https://clarius.com/">ultrasound</a> are fully commercialized. Other more portable imaging devices including <a href="https://physicsworld.com/a/portable-battlefield-mri-comes-out-of-the-lab/" data-href="https://physicsworld.com/a/portable-battlefield-mri-comes-out-of-the-lab/">MRI</a> and CT, will surely appear as the decentralized care system matures. Many are already in the research and development phase. Perhaps with machine learning and better data management, the newer and smaller devices will provide even more accurate assessment than its larger and more expensive predecessor.</p>
<p>&nbsp;</p>
<p><strong>&nbsp; &nbsp; &nbsp;c. Treatment</strong>: As a starter, <a href="https://www.healthleadersmedia.com/innovation/startups-get-head-start-health-system-prescription-innovations" data-href="https://www.healthleadersmedia.com/innovation/startups-get-head-start-health-system-prescription-innovations">ongoing innovations</a> in remote prescription and automated prescription dispensing are rolling out. In dentistry, with the advancement in 3D scanning, 3D printing, and further optimized digital workflow, the clear aligner business is getting further physically decentralized with the appearance of products like <a href="https://smiledirectclub.com/" data-href="https://smiledirectclub.com/">Smile Direct Club</a>, where there is a significant reduction of in-office time/cost for the patients. Decentralized manufacturing offered by 3D printing and milling allows for on-demand manufacturing of personalized medical devices, reducing the necessity of inventory or a central supplier. The 3D printed medical devices can range from arm braces to surgical implants. Additionally, “treatment” does not always mean surgery and dispensary of medications. Mental health, for example, can deliver effective therapy to patients via telemedicine, AR/VR, already.</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p><strong>2. Logical Decentralization </strong>— In the past, healthcare centralization became necessary because of the accumulation of medical knowledge and advancement in technologies. On top of a century-old healthcare education hierarchy, these resulted in growing knowledge asymmetry between patients and healthcare providers, and skill asymmetry among different groups of healthcare providers. However, with emerging healthcare technologies, such asymmetry will be reduced.</p>
<p>&nbsp;</p>
<p><strong>&nbsp; &nbsp; &nbsp; a. Upskilling of a lower skilled worker to perform more complex work/procedure</strong>. For some care providers, this is possible because “skill amplification” or “upskilling”. The demand for more and better healthcare was not met with a growing aging population, and the healthcare cost is reaching an astronomical new high, such skill-augmentation or “upskilling” will be a reasonable solution to the crisis. In fact, the trend is already there: physician assistants and nurse practitioners are becoming a more dominant workforce in the primary and acute care setting. A significant portion of radiological interpretation is already currently <strong>not</strong> done by radiologists (often because of not enough radiologists available at a certain location or not available at certain hours). More dentists are now able to perform more complex dental surgeries with the help of 3D-printed surgical guides or robots without having to go through expensive and often exclusive training. The examples are and will be everywhere.</p>
<p>&nbsp;</p>
<p><strong>&nbsp; &nbsp; &nbsp; b. Informed patients with more data to choose. </strong>With less knowledge asymmetry, the patient can play a bigger role in making a decision on his/her own care, thus decreasing the authority of a healthcare organization or provider. This can be done by providing patients with more tools and channels to digest their healthcare data. Various consumer-based healthcare and wellness startups are now playing the role of the healthcare educator, from genomics, biometrics, to various diagnostic tests. Perhaps one day, Dr. Google can generate search results that are actually based on the individual patient’s existing healthcare data, therefore directing one’s next step in care more accurately. Informed patients will translate to more responsible patients, who will also decrease medical errors either at the level of a healthcare provider or at the level of the healthcare system.</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p><strong>3. Political Decentralization</strong> — Physical and logical decentralization of healthcare is already taking place. However, the degree of decentralization will eventually depend on the degree of political decentralization. Currently, it is hard to imagine decentralizing the role played by many government entities (like FDA), large professional organizations (such as AMA) that setup practice guidelines, or the civil law relevant to healthcare delivery. These authorities play critical roles to protect patients’ safety and safeguard consumer rights. That said, layers of bureaucracy and lobby groups often form around these authorities. These byproducts of political centralization are often obstructionists to change, since maintaining status-quo is their primary responsibility. Will a nurse one day perform an appendectomy with robotic assistance? Will computer replace 80% doctors? Technically possible, but politically not. Or not yet.</p>
<p><a href="https://3dheals.com/decentralized-healthcare%e2%80%8a-%e2%80%8apart-i-cooler-than-bitcoins-but-what-is-it/">https://3dheals.com/decentralized-healthcare%e2%80%8a-%e2%80%8apart-i-cooler-than-bitcoins-but-what-is-it/</a></p>
<p><a href="https://3dheals.com/idea-to-implementation-tactical-issues-image-acquisition-and-protocoling/">https://3dheals.com/idea-to-implementation-tactical-issues-image-acquisition-and-protocoling/</a></p>
<p>The post <a href="https://3dheals.com/decentralized-healthcare-part-2-breaking-it-all-down/">Decentralized Healthcare — Part II: Breaking It All Down</a> appeared first on <a href="https://3dheals.com">3DHeals</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://3dheals.com/decentralized-healthcare-part-2-breaking-it-all-down/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>2019 J.P. Morgan Post-Event Thoughts — 3D Printing Off the Menu</title>
		<link>https://3dheals.com/2019-jp-morgan-post-event-thoughts/</link>
					<comments>https://3dheals.com/2019-jp-morgan-post-event-thoughts/#respond</comments>
		
		<dc:creator><![CDATA[Jenny Chen, M.D.]]></dc:creator>
		<pubDate>Mon, 14 Jan 2019 02:04:10 +0000</pubDate>
				<category><![CDATA[Blog]]></category>
		<category><![CDATA[Healthcare 3D Printing Community]]></category>
		<category><![CDATA[Investing]]></category>
		<category><![CDATA[Two Cents]]></category>
		<category><![CDATA[3D-printing]]></category>
		<category><![CDATA[artificial intelligence]]></category>
		<category><![CDATA[CFIUS]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[fundraising]]></category>
		<category><![CDATA[investing]]></category>
		<category><![CDATA[JP Morgan]]></category>
		<category><![CDATA[JPM19]]></category>
		<category><![CDATA[WSGR]]></category>
		<guid isPermaLink="false">https://3dheals.com/?p=12244</guid>

					<description><![CDATA[<p><a href="https://3dheals.com">3DHeals - Discover 3D Bioprinting and Healthcare Innovations</a></p>
<p>(Originally published on &#8220;Two Cents&#8221; by Jenny Chen, M.D.) J.P.Morgan Healthcare Conference&#160;attracts thousands of healthcare startups and investors from all over the world to San Francisco each January and is possibly one of the most impactful healthcare technology investment forums in the world. The city is overwhelmed with a slew of startup founders, investors, and [&#8230;]</p>
<p>The post <a href="https://3dheals.com/2019-jp-morgan-post-event-thoughts/">2019 J.P. Morgan Post-Event Thoughts — 3D Printing Off the Menu</a> appeared first on <a href="https://3dheals.com">3DHeals</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><a href="https://3dheals.com">3DHeals - Discover 3D Bioprinting and Healthcare Innovations</a></p>
<p>(Originally published on &#8220;<a href="https://medium.com/from-desktop-of-jc/2019-j-p-morgan-post-event-thoughts-3d-printing-off-the-menu-9d06dc93dd9b">Two Cents</a>&#8221; by Jenny Chen, M.D.)</p>
<p id="ae41" class="graf graf--p graf-after--figure"><a class="markup--anchor markup--p-anchor" href="https://www.jpmorgan.com/global/healthcareconference" target="_blank" rel="nofollow noopener" data-href="https://www.jpmorgan.com/global/healthcareconference">J.P.Morgan Healthcare Conference</a>&nbsp;attracts thousands of healthcare startups and investors from all over the world to San Francisco each January and is possibly one of the most impactful healthcare technology investment forums in the world. The city is overwhelmed with a slew of startup founders, investors, and service providers, each with their own ambitions and hopes and their best games in networking. Every SF bar is occupied by corporate receptions, and even hotel lounges start to charge a hefty hourly fee so that people can simply sit down and have a meeting. (Secret: The Westfield Mall food court is free.)</p>
<p class="graf graf--p graf-after--figure">In addition to the main conference hosted by JP Morgan, many other conferences with related themes also took place with the same goal of connecting healthcare startups and investors, and in between service providers. Some of the notable events include&nbsp;<a class="markup--anchor markup--p-anchor" href="http://www.resiconference.com/" target="_blank" rel="nofollow noopener" data-href="http://www.resiconference.com/">RESI</a>&nbsp;(Redefining Early Stage Investment), many medtech events organized by&nbsp;<a class="markup--anchor markup--p-anchor" href="https://www.wsgr.com/WSGR/Display.aspx?SectionName=events" target="_blank" rel="nofollow noopener" data-href="https://www.wsgr.com/WSGR/Display.aspx?SectionName=events">WSGR</a>, and high-level healthcare forums by&nbsp;<a class="markup--anchor markup--p-anchor" href="https://www.mwe.com/events/jpm-2019/" target="_blank" rel="nofollow noopener" data-href="https://www.mwe.com/events/jpm-2019/">McDermott Will &amp; Emery</a>. By Tuesday, I was already exhausted from all the networking, conferencing, and receptions, but I took as many notes as I could, and here are some trends and tips I observed. Hopefully, these will be helpful to the&nbsp;<strong class="markup--strong markup--p-strong">3DHEALS community</strong>, which also hold our first successful JP Morgan reception with our partners at&nbsp;<a class="markup--anchor markup--p-anchor" href="https://www.nixonpeabody.com/en" target="_blank" rel="nofollow noopener" data-href="https://www.nixonpeabody.com/en">Nixon Peabody</a>.</p>
<p id="0603" class="graf graf--p graf-after--p"><strong class="markup--strong markup--p-strong">1.</strong>&nbsp;<strong class="markup--strong markup--p-strong">Less “Disruption” and more “Integration”.</strong></p>
<p id="056c" class="graf graf--p graf-after--p">Throughout all the conferences I attended, there is a definite trend towards a change in presentation. In the homeland of Disrupt SF (TechCrunch) and rebellious history of the bay area, the switch of attitudes shows a new level of humbleness and wisdom after years of attempted, and perhaps unsuccessful, “disruptive” healthcare innovations. There is a growing trend of startups being more “inclusive” towards healthcare providers throughout product development and a lot more emphasis on technology integration with existing healthcare workflow. This is especially obvious in the realm of AI (artificial intelligence) based startups, since replacing the healthcare workforce used to be a more touted endpoint.</p>
<p id="ff39" class="graf graf--p graf-after--p"><strong class="markup--strong markup--p-strong">2.</strong>&nbsp;<strong class="markup--strong markup--p-strong">Artificial Intelligence, or “Neural Learning”?</strong></p>
<p id="fa4e" class="graf graf--p graf-after--p">No, not 3D printing (or bioprinting). A.I. remains to be the buzzword in healthcare this year. But people in industries focusing on decentralized manufacturing, automation, and robotics should all take notes.</p>
<p id="8d88" class="graf graf--p graf-after--p">As one investor tweeted, “ After hearing “We use AI” 4,345,812 times at&nbsp;<a class="markup--anchor markup--p-anchor" href="https://twitter.com/hashtag/jpm19?src=hash" target="_blank" rel="nofollow noopener" data-href="https://twitter.com/hashtag/jpm19?src=hash">#jpm19</a>, I just got told by a company “oh no we’re not just another AI company…we use neural learning” and my eyes rolled so far back in my head they popped out the back and rolled down market street. If seen please return them to me…” (<a class="markup--anchor markup--p-anchor" href="https://twitter.com/geoffclapp" target="_blank" rel="nofollow noopener" data-href="https://twitter.com/geoffclapp"><strong class="markup--strong markup--p-strong">@</strong>geoffclapp</a>)</p>
<figure id="bb80" class="graf graf--figure graf-after--p">
<div class="aspectRatioPlaceholder is-locked">
<div class="aspectRatioPlaceholder-fill"><img loading="lazy" decoding="async" class="alignnone size-medium wp-image-12247" src="https://3dheals.com/wp-content/uploads/2019/01/Screen-Shot-2019-01-13-at-5.16.47-PM-300x216.jpg" alt="" width="300" height="216" srcset="https://3dheals.com/wp-content/uploads/2019/01/Screen-Shot-2019-01-13-at-5.16.47-PM-300x216.jpg 300w, https://3dheals.com/wp-content/uploads/2019/01/Screen-Shot-2019-01-13-at-5.16.47-PM.jpg 307w" sizes="auto, (max-width: 300px) 100vw, 300px" /></div>
<div class="progressiveMedia js-progressiveMedia graf-image is-canvasLoaded is-imageLoaded" data-image-id="1*t79gcDF710DoToY7UzXpRQ.png" data-width="1228" data-height="882" data-action="zoom" data-action-value="1*t79gcDF710DoToY7UzXpRQ.png" data-scroll="native"><canvas class="progressiveMedia-canvas js-progressiveMedia-canvas" width="75" height="53"><img loading="lazy" decoding="async" class="alignnone size-medium wp-image-12246" src="https://3dheals.com/wp-content/uploads/2019/01/jehyun-sung-477894-unsplash-300x192.jpg" alt="" width="300" height="192" srcset="https://3dheals.com/wp-content/uploads/2019/01/jehyun-sung-477894-unsplash-300x192.jpg 300w, https://3dheals.com/wp-content/uploads/2019/01/jehyun-sung-477894-unsplash-447x287.jpg 447w, https://3dheals.com/wp-content/uploads/2019/01/jehyun-sung-477894-unsplash.jpg 521w" sizes="auto, (max-width: 300px) 100vw, 300px" /> <img loading="lazy" decoding="async" class="alignnone size-medium wp-image-12247" src="https://3dheals.com/wp-content/uploads/2019/01/Screen-Shot-2019-01-13-at-5.16.47-PM-300x216.jpg" alt="" width="300" height="216" srcset="https://3dheals.com/wp-content/uploads/2019/01/Screen-Shot-2019-01-13-at-5.16.47-PM-300x216.jpg 300w, https://3dheals.com/wp-content/uploads/2019/01/Screen-Shot-2019-01-13-at-5.16.47-PM.jpg 307w" sizes="auto, (max-width: 300px) 100vw, 300px" /><img loading="lazy" decoding="async" class="alignnone size-medium wp-image-12247" src="https://3dheals.com/wp-content/uploads/2019/01/Screen-Shot-2019-01-13-at-5.16.47-PM-300x216.jpg" alt="" width="300" height="216" srcset="https://3dheals.com/wp-content/uploads/2019/01/Screen-Shot-2019-01-13-at-5.16.47-PM-300x216.jpg 300w, https://3dheals.com/wp-content/uploads/2019/01/Screen-Shot-2019-01-13-at-5.16.47-PM.jpg 307w" sizes="auto, (max-width: 300px) 100vw, 300px" /></canvas></div>
</div>
</figure>
<p id="8fef" class="graf graf--p graf-after--figure">The fervor is fueled a general dissatisfaction with existing healthcare systems (anywhere in the world), a number of&nbsp;<a class="markup--anchor markup--p-anchor" href="https://www.techradar.com/news/healthcare-leads-the-way-when-it-comes-to-ai-investment" target="_blank" rel="nofollow noopener" data-href="https://www.techradar.com/news/healthcare-leads-the-way-when-it-comes-to-ai-investment">tech giant’s</a>&nbsp;involvements lately, an economic drive of democratizing high-level skills to lower-skill workers, and a more&nbsp;<a class="markup--anchor markup--p-anchor" href="https://www.healthimaging.com/topics/artificial-intelligence/2018-cmimi-fda-discusses-regulation-ai-imaging-devices" target="_blank" rel="nofollow noopener" data-href="https://www.healthimaging.com/topics/artificial-intelligence/2018-cmimi-fda-discusses-regulation-ai-imaging-devices">well-defined FDA clearance pathway</a>. An A.I. based startup can now reportedly get FDA 510(k) clearance 5–8 months. Reportedly. The main challenge to investors will now be over-valuation. The main challenge to startups will be real returns, from reimbursement to non-incremental clinical benefits.</p>
<p id="f2b3" class="graf graf--p graf-after--p"><strong class="markup--strong markup--p-strong">3.</strong>&nbsp;<strong class="markup--strong markup--p-strong">Money from Asia</strong></p>
<p id="94e2" class="graf graf--p graf-after--p graf--trailing">During JPM19, there appears to be a sudden surge of Chinese and Asian investors. Even in a city like SF, it is unusual. There were several sessions during&nbsp;<a class="markup--anchor markup--p-anchor" href="http://www.resiconference.com/" target="_blank" rel="nofollow noopener" data-href="http://www.resiconference.com/">RESI</a>&nbsp;focusing on fundraising from China or Asia. China/Asia clearly has a surplus of capital, and U.S./European based startups seem to be the safer bets due better-defined political, legal, and economic structures. However, not all money is equal. Notably,&nbsp;<a class="markup--anchor markup--p-anchor" href="https://home.treasury.gov/policy-issues/international/the-committee-on-foreign-investment-in-the-united-states-cfius" target="_blank" rel="nofollow noopener" data-href="https://home.treasury.gov/policy-issues/international/the-committee-on-foreign-investment-in-the-united-states-cfius">CFIUS</a>&nbsp;was repeatedly mentioned during several of my meetings. It is a government entity authorized to review investment/transactions involving foreign investment in the United States, in order to determine the effect of such transactions on the national security of the United States. Given the current volatile China-US relationship, and volatile international relationships in general, tread carefully is probably the best advice to startups and investors alike, since no one seems to know where the world is going next.</p>
<p>https://3dheals.com/decentralized-healthcare%e2%80%8a-%e2%80%8apart-i-cooler-than-bitcoins-but-what-is-it/</p>
<p>The post <a href="https://3dheals.com/2019-jp-morgan-post-event-thoughts/">2019 J.P. Morgan Post-Event Thoughts — 3D Printing Off the Menu</a> appeared first on <a href="https://3dheals.com">3DHeals</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://3dheals.com/2019-jp-morgan-post-event-thoughts/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Gottlieb Shake-Up Coming To FDA</title>
		<link>https://3dheals.com/gottlieb-shake-up-coming-to-fda/</link>
					<comments>https://3dheals.com/gottlieb-shake-up-coming-to-fda/#respond</comments>
		
		<dc:creator><![CDATA[Paul D'Urso]]></dc:creator>
		<pubDate>Sun, 16 Dec 2018 23:13:12 +0000</pubDate>
				<category><![CDATA[Blog]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[healthcare]]></category>
		<category><![CDATA[medical]]></category>
		<category><![CDATA[medical device]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Technology]]></category>
		<guid isPermaLink="false">https://3dheals.com/?p=11823</guid>

					<description><![CDATA[<p><a href="https://3dheals.com">3DHeals - Discover 3D Bioprinting and Healthcare Innovations</a></p>
<p>(This was originally published on Linkedin) Do you think that Community Based Personalised Healthcare will be enabled by a new process based regulatory system? The U.S. Senate approved Scott Gottlieb, M.D. as the next FDA Commissioner on May 9 by a vote of 52 to 47. Deregulation Advocate Gottlieb has a track record as an [&#8230;]</p>
<p>The post <a href="https://3dheals.com/gottlieb-shake-up-coming-to-fda/">Gottlieb Shake-Up Coming To FDA</a> appeared first on <a href="https://3dheals.com">3DHeals</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><a href="https://3dheals.com">3DHeals - Discover 3D Bioprinting and Healthcare Innovations</a></p>
<h4><em>(This was originally published on <a href="https://www.linkedin.com/pulse/gottlieb-shake-up-coming-fda-paul-s-d-urso/">Linkedin</a>)</em></h4>
<h2>Do you think that Community Based Personalised Healthcare will be enabled by a new process based regulatory system?</h2>
<p>The U.S. Senate approved Scott Gottlieb, M.D. as the next FDA Commissioner on May 9 by a vote of 52 to 47.</p>
<h4>Deregulation Advocate</h4>
<p>Gottlieb has a track record as an advocate for deregulation and was on President Trump’s transition team. Earlier, he was a senior adviser to the presidential campaign of Wisconsin Governor Scott Walker. In addition to being an industry consultant, he previously served as a deputy FDA commissioner and a high-ranking official at the Centers for Medicare and Medicaid Services (CMS) during the George W. Bush administration.</p>
<p>He&#8217;s also been an advocate of speeding the approval process through shorter trials. He has also criticized the agency as being too restrictive in its views on “off-label” promotions. With federal courts applying First Amendment free speech rights to device manufacturers providing truthful &#8220;off-label&#8221; information, we are likely to see dramatic changes in that area.</p>
<p>“Longer, larger trials that require drug makers to evaluate &#8216;hard&#8217; endpoints (like how long a cancer patient lives) rather than &#8216;surrogate&#8217; endpoints (like a drug&#8217;s ability to shrink tumors) give FDA reviewers more statistical confidence. Reviewers prefer these drawn-out trials because they insulate the FDA from critics who say that it isn&#8217;t focused enough on safety. But bigger trials increase the time needed to develop a drug, keeping it out of the hands of patients,” he wrote in the&nbsp;<em>Wall Street Journal</em>&nbsp;in 2010.</p>
<p>Gottlieb is expected to implement FDA mandates in the recently passed 21st Century Cures Act, which is, among other things, designed to speed the approval process by relaxing certain clinical trial requirements. The Act requires the FDA to consider the use of &#8220;real world evidence,&#8221; including patient reports, anecdotal data and observational studies.</p>
<h4>Industry Ties</h4>
<p>Gottlieb is a physician and venture capitalist. As is usual with FDA commissioner nominees, ties to industry is a contentious focus of his Senate hearings. According to federal ethics filings, Gottlieb plans to recuse himself for a year from agency decisions involving more than 20 companies that he has worked for, invested in or had some other kind of financial relationship with.</p>
<p>According to filings, he is also selling off financial interests and resigning from positions in several companies. For example, as a partner in the venture capital firm New Enterprise Associates, Gottlieb invested in a laboratory-testing company called American Pathology Partners and five other firms.</p>
<p>As a managing director at the investment banking firm T.R. Winston &amp; Co., he has investments in 13 client companies, including one that is working on treatments for sickle cell disease and another that is focusing on Duchenne muscular dystrophy.</p>
<p>According to the&nbsp;<em>Wall Street Journal</em>, Gottlieb made $3 million in gross income during 2016 and through March 1, 2017. That amount included $1.85 million from T.R. Winston.</p>
<h4>New Look FDA</h4>
<p>If Gottlieb is able to put his stamp on the agency, we are likely to see faster pathways to approvals, a stronger emphasis on post approval data collection and more information flowing between device makers and physicians.</p>
<p>What we don&#8217;t know is whether or not Gottlieb will have to follow President Trump’s orders to repeal two regulations for every new one. Whether he will have to accept deep budget cuts that could affect his ability to implement the 21st Century Cures Act and how far Trump will push him in his stated goal to “slash restraints” at the FDA to speed up what the President has called a “slow and burdensome” process of drug approvals.</p>
<p>&nbsp;</p>
<p><b>About the Author:&nbsp;</b></p>
<p><a href="https://www.linkedin.com/in/paulsdurso/">Dr. Paul D&#8217;Urso</a></p>
<p><img loading="lazy" decoding="async" class="alignnone size-full wp-image-6011" src="https://3dheals.com/wp-content/uploads/2018/01/Paul-DUrso.jpg" alt="" width="190" height="143"></p>
<p>Dr. Paul S D&#8217;Urso is a Neurosurgeon and the Founder &amp; Executive Chairman of the Anatomics group of companies in Melbourne, Australia. Dr. D&#8217;Urso&#8217;s unique experience in research, clinical practice, teaching, commercialization, and medico-legal opinion has made him an internationally recognized Australian neurosurgeon, scientist, and innovator.&nbsp; Dr D&#8217;Urso invented the technology of BioModelling with groundbreaking PhD research and founded Anatomics, one of the worlds most innovative medical software &amp; device companies in 1995. Anatomics is a nonprofit company that has helped many thousands of severely affected patients and is committed to implementing the vision of &#8216;Community Based Personalised Healthcare&#8217; via its AnatomicsRx software architecture.<br />
Dr D’Urso was a fellow at the Cambridge University Neurosurgery unit and a clerk at Harvard Medical School. He has published and presented over 130 scientific papers, holds multiple international patents and has won over 30 prestigious research prizes.</p>
<p>As a medical practitioner for over 28 years, Dr D’Urso has accumulated a wealth of experience at Court in all jurisdictions. Dr D&#8217;Urso provides expert opinion for plaintiffs, defendants and for the Crown and is accredited by prestigious medico-legal opinion services.</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>The post <a href="https://3dheals.com/gottlieb-shake-up-coming-to-fda/">Gottlieb Shake-Up Coming To FDA</a> appeared first on <a href="https://3dheals.com">3DHeals</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://3dheals.com/gottlieb-shake-up-coming-to-fda/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Formnext 2018 Healthcare: Production is the Key</title>
		<link>https://3dheals.com/formnext-2018-healthcare-production-is-the-key/</link>
					<comments>https://3dheals.com/formnext-2018-healthcare-production-is-the-key/#comments</comments>
		
		<dc:creator><![CDATA[Fabio Sanches Sant'Ana]]></dc:creator>
		<pubDate>Fri, 14 Dec 2018 09:09:40 +0000</pubDate>
				<category><![CDATA[3dheals Community Activities]]></category>
		<category><![CDATA[Blog]]></category>
		<category><![CDATA[3D-printing]]></category>
		<category><![CDATA[3dprinting]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[healthcare]]></category>
		<category><![CDATA[hospital]]></category>
		<category><![CDATA[medical]]></category>
		<category><![CDATA[medical device]]></category>
		<category><![CDATA[regenerative medicine]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[science]]></category>
		<guid isPermaLink="false">https://3dheals.com/?p=11942</guid>

					<description><![CDATA[<p><a href="https://3dheals.com">3DHeals - Discover 3D Bioprinting and Healthcare Innovations</a></p>
<p>Additive Manufacturing is becoming more mature, we can now produce final components in polymers or metals in quantities that make sense in the manufacturing world. In addition, we have full control of this new process, full production was the tone of the show. Machine builders showcased features about fast builds, parts quantities measured in pieces per year, and process automation like heat treatment and build plate management inside the machines.  Most of the demo parts were fully filled build plates.</p>
<p>The post <a href="https://3dheals.com/formnext-2018-healthcare-production-is-the-key/">Formnext 2018 Healthcare: Production is the Key</a> appeared first on <a href="https://3dheals.com">3DHeals</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><a href="https://3dheals.com">3DHeals - Discover 3D Bioprinting and Healthcare Innovations</a></p>
<p>Last November, &nbsp;Frankfurt, Germany received the biggest crowd in Additive Manufacturing. Formnext2018 is the major showcase for the AM technology and its accessories. Formnext 2018 filled two halls of Frankfurt Messe, which means a double than last year.</p>
<p>Additive manufacturing is becoming more mature, we can now produce final components in polymers or metals in quantities that make sense in the manufacturing world. In addition, we have full control of this new process, full production was the tone of the show. Machine builders showcased features about fast builds, parts quantities measured in pieces per year, and process automation like heat treatment and build plate management inside the machines. &nbsp;Most of the demo parts were fully filled build plates.</p>
<p><div id="attachment_11945" style="width: 310px" class="wp-caption alignleft"><img loading="lazy" decoding="async" aria-describedby="caption-attachment-11945" class="wp-image-11945 size-medium" src="https://3dheals.com/wp-content/uploads/2018/12/3Formnext-min-300x177.jpg" alt="" width="300" height="177" srcset="https://3dheals.com/wp-content/uploads/2018/12/3Formnext-min-300x177.jpg 300w, https://3dheals.com/wp-content/uploads/2018/12/3Formnext-min-447x264.jpg 447w, https://3dheals.com/wp-content/uploads/2018/12/3Formnext-min-768x453.jpg 768w, https://3dheals.com/wp-content/uploads/2018/12/3Formnext-min-1024x604.jpg 1024w, https://3dheals.com/wp-content/uploads/2018/12/3Formnext-min.jpg 1254w" sizes="auto, (max-width: 300px) 100vw, 300px" /><p id="caption-attachment-11945" class="wp-caption-text">Picture Courtesy of Materialise</p></div></p>
<p><span style="font-weight: 400;">On the healthcare side, companies presented equipment capable of making biomodels with multiple textures and materials, models that can simulate surgical procedures perfectly; polymer cutting guides to make precise bone resections; &nbsp;equipment capable of making polymer and metal implants with the right geometry, properties, and osseointegration;and computer systems capable of create shapes based on human body physiology. </span></p>
<p>&nbsp;</p>
<p><img loading="lazy" decoding="async" class="aligncenter wp-image-11959" src="https://3dheals.com/wp-content/uploads/2018/12/efb286a7-4b39-4998-b9e1-ccec98e02d03-min-1024x576.jpg" alt="" width="640" height="360" srcset="https://3dheals.com/wp-content/uploads/2018/12/efb286a7-4b39-4998-b9e1-ccec98e02d03-min-1024x576.jpg 1024w, https://3dheals.com/wp-content/uploads/2018/12/efb286a7-4b39-4998-b9e1-ccec98e02d03-min-447x251.jpg 447w, https://3dheals.com/wp-content/uploads/2018/12/efb286a7-4b39-4998-b9e1-ccec98e02d03-min-300x169.jpg 300w, https://3dheals.com/wp-content/uploads/2018/12/efb286a7-4b39-4998-b9e1-ccec98e02d03-min-768x432.jpg 768w, https://3dheals.com/wp-content/uploads/2018/12/efb286a7-4b39-4998-b9e1-ccec98e02d03-min.jpg 1280w" sizes="auto, (max-width: 640px) 100vw, 640px" /></p>
<p>Most current build preparation systems, with optional functions or not, can simulate the build process with good precision and geometrical correction about the thermal, stress, and supports displacement, in laser powder bed fusion process. Similar systems will be available to other AM process soon. New supports calculation algorithms are making the built more stable and repeatable. DED and EBM processes are being supported by some systems and should have the same coverage as FDM and LPBF processes in a short time.</p>
<p>&nbsp;</p>
<p><img loading="lazy" decoding="async" class="wp-image-11958 size-medium alignleft" src="https://3dheals.com/wp-content/uploads/2018/12/e0d78039-8581-4253-8133-f09c67722225-min-300x169.jpg" alt="" width="300" height="169" srcset="https://3dheals.com/wp-content/uploads/2018/12/e0d78039-8581-4253-8133-f09c67722225-min-300x169.jpg 300w, https://3dheals.com/wp-content/uploads/2018/12/e0d78039-8581-4253-8133-f09c67722225-min-447x251.jpg 447w, https://3dheals.com/wp-content/uploads/2018/12/e0d78039-8581-4253-8133-f09c67722225-min-768x432.jpg 768w, https://3dheals.com/wp-content/uploads/2018/12/e0d78039-8581-4253-8133-f09c67722225-min-1024x576.jpg 1024w, https://3dheals.com/wp-content/uploads/2018/12/e0d78039-8581-4253-8133-f09c67722225-min.jpg 1280w" sizes="auto, (max-width: 300px) 100vw, 300px" /></p>
<p>&nbsp;</p>
<p><span style="font-weight: 400;">What is called by the industry post processing, I call finishing, &nbsp;are advancing fast. Things like automated support removal, build plate separation, heat treatment and surface finish are being really integrated into the chain and had a big exposure in the show. </span></p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p><img loading="lazy" decoding="async" class="wp-image-11956 size-medium alignright" src="https://3dheals.com/wp-content/uploads/2018/12/980abdb0-7d80-43b2-8d10-e2a32fb4c7a5-min-300x169.jpg" alt="" width="300" height="169" srcset="https://3dheals.com/wp-content/uploads/2018/12/980abdb0-7d80-43b2-8d10-e2a32fb4c7a5-min-300x169.jpg 300w, https://3dheals.com/wp-content/uploads/2018/12/980abdb0-7d80-43b2-8d10-e2a32fb4c7a5-min-447x251.jpg 447w, https://3dheals.com/wp-content/uploads/2018/12/980abdb0-7d80-43b2-8d10-e2a32fb4c7a5-min-768x432.jpg 768w, https://3dheals.com/wp-content/uploads/2018/12/980abdb0-7d80-43b2-8d10-e2a32fb4c7a5-min-1024x576.jpg 1024w, https://3dheals.com/wp-content/uploads/2018/12/980abdb0-7d80-43b2-8d10-e2a32fb4c7a5-min.jpg 924w" sizes="auto, (max-width: 300px) 100vw, 300px" /></p>
<p><span style="font-weight: 400;">ASTM and ISO held a joint workshop discussing the standards development for additive, all the most important officers of both organizations were present and a good panel with the biggest standards specialists in industry discussed the main challenges we face while developing it. </span></p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p><span style="font-weight: 400;">Additive manufacturing is a new technology, now available for the manufacturing of real-life products. AM has the innovation capacity for any sector, from fixture devices to medical devices, &nbsp;aerospace parts, to tooling and production equipment to complete final automotive components. AM should no longer be seen as a substitute to well-established process that make products properly with well-adjusted supply chains. It is important to keep in mind that AM is initial, final and complimentary to processes like machining and injection molding in making large quantities of parts. These traditional processes have precision requirements not met by metal AM yet. By being a polymeric or metallurgical process, AM &nbsp;&nbsp;has its limitations and needs proper use.</span></p>
<p><img loading="lazy" decoding="async" class="aligncenter wp-image-11954" src="https://3dheals.com/wp-content/uploads/2018/12/47ce69d8-5004-4be1-86e5-9f399671c5fc-min-1024x576.jpg" alt="" width="640" height="360" srcset="https://3dheals.com/wp-content/uploads/2018/12/47ce69d8-5004-4be1-86e5-9f399671c5fc-min-1024x576.jpg 1024w, https://3dheals.com/wp-content/uploads/2018/12/47ce69d8-5004-4be1-86e5-9f399671c5fc-min-447x251.jpg 447w, https://3dheals.com/wp-content/uploads/2018/12/47ce69d8-5004-4be1-86e5-9f399671c5fc-min-300x169.jpg 300w, https://3dheals.com/wp-content/uploads/2018/12/47ce69d8-5004-4be1-86e5-9f399671c5fc-min-768x432.jpg 768w, https://3dheals.com/wp-content/uploads/2018/12/47ce69d8-5004-4be1-86e5-9f399671c5fc-min.jpg 924w" sizes="auto, (max-width: 640px) 100vw, 640px" /></p>
<p><span style="font-weight: 400;">Additive Manufacturing is a process to add to the traditional manufacturing process. It must be integrated into the factories, must be understood and developed. Yes, additive machines and systems have its “marvelous” features as well as challenges, but our industry will progress to implement and improve itself. We can soon experience an exponential jump to better-designed products and massively improved manufacturing. Formnext2018 confirmed we are on the right path!</span></p>
<p>&nbsp;</p>
<p><img loading="lazy" decoding="async" class="wp-image-11953 aligncenter" src="https://3dheals.com/wp-content/uploads/2018/12/2c50c1e3-e247-4a11-85a7-24481af6ed9e-min-1024x576.jpg" alt="" width="640" height="360"></p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<h4>About the Author:</h4>
<p><img loading="lazy" decoding="async" class="alignleft wp-image-11952 size-medium" src="https://3dheals.com/wp-content/uploads/2018/12/Fabio-min-300x300.jpeg" alt="" width="300" height="300" srcset="https://3dheals.com/wp-content/uploads/2018/12/Fabio-min-300x300.jpeg 300w, https://3dheals.com/wp-content/uploads/2018/12/Fabio-min-245x245.jpeg 245w, https://3dheals.com/wp-content/uploads/2018/12/Fabio-min-100x100.jpeg 100w, https://3dheals.com/wp-content/uploads/2018/12/Fabio-min-447x447.jpeg 447w, https://3dheals.com/wp-content/uploads/2018/12/Fabio-min-150x150.jpeg 150w, https://3dheals.com/wp-content/uploads/2018/12/Fabio-min-250x250.jpeg 250w, https://3dheals.com/wp-content/uploads/2018/12/Fabio-min.jpeg 600w" sizes="auto, (max-width: 300px) 100vw, 300px" /></p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p><strong>Fabio Sant’Ana</strong> has Precision Mechanics degree and Business Administration Bachelor’s , born and raised in São Paulo he has 25 years experience in helping companies to aquire and take full advantage of 3d Machining and Additive Manufacturing Equipment . Entrepreneur and knowledge avid is member of stardarts organizations ASTM F42 Additive Manufacturing , ABNT CEE-261 Manufatura Aditiva e ABNT CB-26 Odonto-Médico-Hospitalar . CAD/CAM , Surface Modelling and EBM specialist he is passionate in connect people and companies to the right tools to accomplish the mission.</p>
<p>&nbsp;</p>
<p>The post <a href="https://3dheals.com/formnext-2018-healthcare-production-is-the-key/">Formnext 2018 Healthcare: Production is the Key</a> appeared first on <a href="https://3dheals.com">3DHeals</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://3dheals.com/formnext-2018-healthcare-production-is-the-key/feed/</wfw:commentRss>
			<slash:comments>1</slash:comments>
		
		
			</item>
	</channel>
</rss>
